1 Roche

Half year results 2012

July 26, 2012 Basel

2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website – www.roche.com 3 All mentioned trademarks are legally protected Group Severin Schwan Chief Executive Officer

4 HY 2012: A strong first half

Sales on track for full year guidance • Group and Pharma: +4%1, Diagnostics: +5%1 Pipeline progressed well • Perjeta successfully launched in US • T-DM1 pivotal study (EMILIA) at ASCO • Actemra head-to-head vs. Humira (ADACTA) at EULAR Continuous productivity improvements • Core operating profit further increased by 7%1, Core EPS +8%1 • Operating free cash flow & margin further increased Outlook confirmed • Core EPS growth target ‘high single digit’1 • Attractive dividend policy

5 1 at Constant Exchange Rates HY 2012: Group sales Supporting full-year guidance

2012 2011 change in % CHF m CHF m CHF CER

Pharmaceuticals Division 17,409 16,815 +4 +4

Diagnostics Division 5,014 4,856 +3 +5

Roche Group 22,423 21,671 +3 +4

6 CER=Constant Exchange Rates Increase in operating profit & margin

Group core operating profit (CHF bn) and margin 38.5%

37.2% 38.1% 34.7% 35.0% +7% at CER

8.64 9.16 8.40 8.25 7.63

HY 2008 HY 2009 HY 2010 HY 2011 HY 2012 7 CER=Constant Exchange Rates Strong operating free cash flow and margin

Group operating free cash flow (CHF bn) and margin

32.0%

26.1% 31.6% 28.2% +7% at CER 21.8% 7.17

6.78 6.86 6.43

4.81

HY 2008 HY 2009 HY 2010 HY 2011 HY 2012 8 CER=Constant Exchange Rates HY 2012: +8% Core EPS growth1

+8% at CER

CHF 6.94 6.95 6.68 6.36 5.75

HY 2008 HY 2009 HY 2010 HY 2011 HY 2012 9 1 CER=Constant Exchange Rates 2011/12: Strong progression of pipeline 22 successful late-stage clinical trials

Zelboraf Erivedge MetMAb Herceptin sc Lucentis Avastin dalcetrapib BRIM 3 ERIVANCE NSCLC HANNAH HARBOR TML dal-OUTCOMES

Avastin OC Actemra Perjeta Actemra Actemra MabThera SC OCEANS ACT-Ray CLEOPATRA BUILDER I/II CHERISH SABRINA

2 0 1 1 2012

Avastin+ Avastin+ Tarceva Lucentis T-DM1 Actemra T-DM1 Actemra pemetrexed Herceptin EURTAC RISE Phase II ADACTA EMILIA SUMMACTA AVAPERL AVEREL

Lucentis lebrikizumab Actemra sc GA101 Avastin Avastin RIDE MILLY PhIII Japan GAUSS AURELIA BEATRICE

10 Positive trials Optimizing value streams in 2012

Reallocate R&D resources into expanding pipeline • Focus portfolio (pRED) • Close Nutley Diagnostics business set-up • Reposition Applied Science • Address tougher environment in Diabetes Care

Cost structure • Finalize remaining part of Operational Excellence • Optimize IT Infrastructure to cope with business needs

Continuous focus on net working capital • Reducing receivables in Southern Europe

11 Roche portfolio: Increasing value through focus

New Molecular Entities

79 76 80 72 11 62 11 59 11 60 8 21 8 23 23 18 40 16

47 20 42 35 36 38

0 2009 2010 2011 HY 2012 HY 2012 before R&D after R&D prioritisation prioritisation Phase I Phase II Phase III + Registration

12 Growing late-stage portfolio Expanding into selected therapeutic franchises

LIP candidates 2012 target: 3 out of 5

Larger (> 1 bn)

Smaller (up to ~1 bn) GA101 Perjeta T-DM1 bitopertin aleglitazar danoprevir MEK 0973 etrolizumab anti-PCSK9 ocrelizumab mericitabine lebrikizumab onartuzumab rontalizumab Bcl-2-sel Inh Potential Filing 2012 2013 2014 2015 2016 2017 onwards Year

Oncology Neuroscience Metabolism Virology Immunology 13 Non risk-adjusted pRED: Reallocate resources & keep R&D costs stable

Reallocate resources into expanding pipeline • Last 18 months 22 out of 26 late stage clinical trials positive • 72 NMEs in clinical development • Expect number of Phase II/III projects to further increase

Reduce complexity • Co-locate pRED management • gRED not affected

Optimize cost structure • Site infrastructure savings (Nutley) • Improve leverage of support functions (ex: chemistry & non-clinical safety)

14 Outlook for 2012 confirmed

Sales growth (CER) Group & Pharma: low to mid-single digit Diagnostics: above market

Operational Excellence savings 2012+: CHF 2.4 bn*

Core EPS growth target High single-digit (CER)

Dividend outlook Continue attractive dividend policy

15 Barring unforeseen events; CER=Constant Exchange Rates; * vs. 2011: CHF 1.8 bn Pharmaceuticals Division Pascal Soriot COO Roche Pharmaceuticals

16 HY 2012: Pharma sales US and International major growth contributors

2012 2011 change in % CHF m CHF m CHF CER Pharmaceuticals Division 17,409 16,815 +4 +4 United States 6,815 6,285 +8 +6 Western Europe 4,000 4,299 -7 -3 Japan 1,943 1,831 +6 +1 International 4,651 4,400 +6 +8

17 CER=Constant Exchange Rates HY 2012: Pharma Division Profitability improvement in a challenging environment

HY 2012 vs. HY 2011 HY 2012 CER growth CHF m % sales Sales 17,409 100.0 4%

Royalties & other op inc 802 4.6 5% Cost of sales -3,486 -20.0 -5% COGS & PC1: -4% M & D -2,751 -15.8 3% R & D -3,587 -20.6 3% G & A -498 -2.9 6% Admin: -1%

Core operating profit 7,889 45.3 9% +7% in CHF

18 CER=Constant Exchange Rates; 1 Period Costs HY 2012: Pharma sales Oncology, Pegasys and Actemra main growth drivers

Herceptin +11%

MabThera/Rituxan +9%

Pegasys +31%

Actemra/RoActemra +39%

Xeloda +14%

Zelboraf NA

Tamiflu -18%

Xenical -52%

CellCept -15% International US NeoRecormon/Epogin -28% Japan Western Europe Boniva/Bonviva -46%

-300 -200 -100 0 100 200 300 400

19 Absolute amounts in CHF m at Constant Exchange Rates (CER) average 2011; all growth rates at CER HY 2012: US Continued strong performance

• Pegasys, Rituxan, Herceptin, Xeloda US: +6%1 main growth contributors • Zelboraf, Erivedge and Perjeta: successful launch to continue in 2H 2012 • Sales growth expected to slow in the 2nd half 2012 – Pegasys: higher 2011 base – Lucentis: further decline expected in AMD

20 1 CER=Constant Exchange Rates HY 2012: Western Europe Growth of strategic products offset by generics and supply constraints

MabThera +6% Oncology: Launch of Zelboraf; volume growth Zelboraf NA for MabThera, Herceptin and Avastin RoActemra +38% (launch in ovarian cancer) RoActemra: Herceptin +3% Increasing market share in Avastin +2% monotherapy segment

Neorec./Epog. -15%

Cellcept -20% Off-patent products Bonviva, CellCept, Xenical decline Xenical -83% after patent loss Mircera -53% Mircera Supply constraints Bonviva -46%

CHF m -70 -50 -30 -10 10 30 50 70 21 Absolute amounts in CHF m at Constant Exchange Rates (CER) average 2011; all growth rates at CER HY 2012: E7 countries Strong growth driven by China and Brazil

+22%1 1000

+79% India 800 -6% Russia +53% Korea +14% Turkey

600 -3% Mexico

400 +37% China

200 +25% Brazil

0 Q1 '11 Q2 '11 Q3 '11 Q4 '11 Q1 '12 Q2 '12

22 1 CER=Constant Exchange Rates; absolute values in CHF m at average 2011 exchange rates China: Roche outgrowing the market

40% 36% 35% 32% 30%

25% 24% 20% 24% 19% 20% 17% 15% 14% 16% 16% 10% Roche 5% Chinese market 0% Q1 '11 Q2 '11 Q3 '11 Q4 '11 Q1 '12

23 Source: Both Roche and Chinese market from IMS Hospital Audits HY 2012: Oncology franchise Avastin back to growth, new products off to a good start Major brands CHF bn CER growth

MabThera/ Continued uptake in 1L maintenance in NHL; longer +9% Rituxan treatment duration; further uptake in CLL Expanded access in emerging markets, increased HER2 Herceptin +11% testing and further uptake in HER2+ gastric cancer Japan: strong uptake in NSCLC and mBC; Avastin +3% EU: launch in ovarian cancer, increased share in mBC Growth driven mainly by US, China and other Int’l Xeloda +14% regions; US growth partially driven by shortage of IV 5FU

Tarceva +8% Growth driven mostly by US and China

US: ~85% market share in BRAF V600 patients; Zelboraf NA approved in EU Q1 2012

Erivedge NA Launched in US Q1 2012

Perjeta NA Launched in US Q2 2012

0.0 1.0 2.0 3.0 4.0 24 CER = Constant Exchange Rates Oncology HY 2012 sales: 10.5 bn Lucentis Continued competitive pressure in wet AMD

US sales CHF m HY 2012 sales: CHF 745 m 800 -5%1 AMD: 700 • Lucentis share declining after launch of Eylea 600 • 0.5 mg PRN dosing PDUFA date: 500 February 2013

400 RVO: Lucentis share stable

300 DME: 200 • FDA advisory committee meeting 26 100 July 2012 0 • PDUFA date: 10 August 2012 HY '08 HY '09 HY '10 HY '11 HY '12

25 1 CER=Constant Exchange Rates AMD=wet age-related macular degeneration; RVO=retinal vein occlusion; DME=diabetic macular edema Actemra: clinical data driving growth

ADACTA study: ACTEMRA vs. Humira week 24

Humira (N = 162) 70% 60% 65% Humira (N = 162) Actemra (N = 163) Actemra(N = 163) 51.5% 60% 50% 49% 50% 47% 39.9% 40% 40% 33% 30% 30% 28% Patients 19.8% 20% 20% 18% 10.5% 10% 10%

0% 0% DAS28 remission ACR 20 ACR 50 ACR70 DAS28 low disease activity (≤3.2) (<2.6)

• Positive subcutaneous data (SUMMACTA) • 1st line biologic filed in US 26 Monotherapy in rheumatoid arthritis: substantial portion of biologic treatment

ACTEMRA market share Biologic therapy today in monotherapy segment*

20%

16% 30% 15% 14%

11% 11% 10% 9% 70% 8% 7% 7% 7% 5% 5% 5% 3% 3% Biologic monotherapy 1% Biologic combination 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 '09 '09 '09 '09 '10 '10 '10 '10 '11 '11 '11 '11 '12 '12

27 * Market share for GE, FR, IT, ESP, UK Perjeta: Initial market feedback positive Significant medical benefit in metastatic BC

Market update

• Launch within one business day of approval • US price reflects high medical benefit • NCCN guidelines endorsed Perjeta as the preferred first-line treatment in mBC in combination with Herceptin

Clinical update

• Overall survival benefit in HER 2+ 1L mBC to be presented by year end • MARIANNE study in combination with T-DM1 (1L mBC): filing expected 2014 • APHINITY study in combination with Herceptin (eBC): filing expected 2016

28 Data to be presented in H2 2012

Actemra Perjeta • SUMMACTA/BREVACTA • CLEOPATRA (1L mBC) Subcutaneous formulation OS data

rontalizumab MabThera SC • ROSE study in lupus • SABRINA (front line follicular phII data NHL) phIII

Herceptin

• HERA 2 years vs. 1 year

Immunology Oncology 29 Hepatitis strategy update Focusing on emerging markets

HCV infected population Strategy focus 40 • Develop IFN-based danoprevir triple combination in emerging 30 markets • IFN-free ANNAPURNA phII study (setrobuvir, mericitabine and 20 danoprevir) to decide about millions IFN-free therapy development

10

0

30 Source: WHO as of May 2006. Major clinical and regulatory news flow

Timeline Compound Indication Milestone Avastin mCRC Ph III TML  pertuzumab 1st line HER2+ mBC US approval  EU approval Erivedge advanced BCC US approval  EU approval (2012/13) Zelboraf metastatic melanoma EU approval  Lucentis DME US approval T-DM1 2nd line HER2+ mBC Ph III EMILIA  2012 Herceptin subcutaneous early HER2+ BC Ph III HANNAH (data presentation)  Herceptin adjuvant HER2+ BC Ph III HERA 2 years vs. 1 year MabThera subcutaneous front-line follicular NHL Ph III  Actemra RA DMARD IR Ph III ADACTA H2H vs. Humira  Actemra subcutaneous RA, moderate to severe Ph III SUMMACTA  BREVACTA Avastin newly diagnosed glioblastoma Ph III AVAglio dalcetrapib Atherosclerosis CV risk red. 2nd interim analysis in H1 2012  2013 GA101 Front line CLL Ph III vs. chemotherapy

bitopertin (GlyT-1) Schizophrenia Ph III (several studies) 31 Oncology and CV outcome studies are event driven, timelines may change Diagnostics Division Daniel O’Day COO Roche Diagnostics

32 HY 2012: Diagnostics Division sales Strong growth in Professional, Molecular and Tissue Diagnostics

2012 2011 change in % CHF m CHF m CHF CER Diagnostics Division 5,014 4,856 +3 +5

Professional Diagnostics 1 2,515 2,360 +7 +9

Diabetes Care 1 1,260 1,316 -4 -2 Molecular Diagnostics 571 544 +5 +6 Applied Science 363 377 -4 -3 Tissue Diagnostics 305 259 +18 +17

33 CER = Constant Exchange Rates 12011 sales restated from Diabetes Care (full year impact CHF –23 m) to Professional Diagnostics (CHF +23 m full year impact) HY 2012: Diagnostics Division Costs increase reflects higher instrument placements and bad debt write-offs

2012 2012 vs. 2011 CHF m % sales CER growth Sales 5,014 100.0 5%

Royalties & other op inc 78 1.6 56% 1 Cost of sales -2,180 -43.5 9% M & D -1,254 -25.0 9% R & D -456 -9.1 7% G & A -204 -4.0 Admin: +8% 10%

* Core operating profit 998 19.9 -5%

34 * Bad-debt expenses had negative impact on the operating margin development of 0.8%p CER = Constant Exchange Rates 1 Cost of goods sold & period cost HY 2012: Diagnostics Division sales Growth driven by Asia Pacific and North America

CHF 5,014 m CER sales growth

1,281 North America 25% Diagnostics Division 5%

North 5% America 348 Latin America 7% EMEA* 1% Asia Pacific 15% Latin 736 13% 2,365 America Asia 284 Japan 6% Pacific 17% EMEA * 47% Japan 7%

35 * Europe, Middle East and Africa CER=Constant Exchange Rates HY 2012: Diagnostics Division highlights

HY 2012 vs. HY 2011 CHF bn CER growth

Professional FDA approval for cobas b 123 POC blood gas analyzer; Dia +9% publication of VISION study; strong immunoassay sales

Diabetes Reimbursement pressures in EMEA region; FDA clearance -2% Care for Accu-Chek Combo pump system; restructuring initiatives

Molecular Strong revenues in blood screening and HCV monitoring; FDA +6% Dia approval of first automated CMV* test

Applied -3% Strong sales to industrial manufacturing customers; continued Science weakness in genomics; restructuring initiatives

EMEA Continued strong sales growth; launch of BenchMark Special Tissue Dia +17% North America RoW Stains and VENTANA iScan HT

0123 36 EMEA=Europe, Middle East and Africa * Cytomegalovirus HY 2012: Professional Diagnostics Strong growth driven by immunoassays

North America +9% Immunoassays +13% 2 new immunoassays launched EMEA +4% • HCV II in the EU and HBc IgM in the US Immunoassays +7%

Japan +12% FDA approval for cobas b 123 Immunoassays +17% POC blood gas analyzer • Fast and reliable results to determine sufficient respiratory support for patients

Asia Pacific +20% Latin America +12% Immunoassays +27% Immunoassays +22% Launch of cobas p 312 • Pre-analytics system that improves automation & workflow for labs

14% immunodiagnostics sales growth in HY 2012

37 EMEA=Europe, Middle East and Africa All growth at CER (Constant Exchange Rates) Providing medical value in a new indication Elecsys® Troponin T test predicts mortality risk after non-cardiac surgery VISION Study publication in JAMA1

• Results from the first 15,133 non-cardiac surgery patients • Peak post-operative troponin levels significantly associated with 30-day mortality • Results will aid physicians assess individual patient risk and tailor therapy

Roche Elecsys® Troponin T hs Assay Latest generation high sensitive troponin T test is a new tool to diagnose AMI2 earlier Roche is the global troponin market leader with 30% share3

38 1 Devereaux et al., JAMA, June 6, 2012-Vol. 307, No. 21; 2Acute Myocardial Infarction; 3 Independent Industry Report Accu-Chek Combo System receives FDA clearance Second US launch from new generation portfolio

Easy glucose testing, bolus advice and insulin Distinct Advantages administration via remote without touching the pump.

Build on Success 36% sales CAGR ex-US1

Market Expansion Well positioned in the growing US IDS market

US Insulin Delivery (IDS) Market2

+4% 989 952

Sales USD m Accu-Chek Combo System Smart meter works as a remote for the pump 2010 2011 39 1 Since launch: 2009-2011; 2 2011 figures from Independent Industry Analysis Improving automation in Pathology Labs New instrument launches by Ventana

BenchMark Special Stains • Performs special stains that enable visualisation of structures and pathogens • Eliminates manual process with full automation

• Large global market opportunity with over 75% of tests currently run manually1

VENTANA iScan HT • Powerful slide scanner with 360 slide capacity, high throughput2, and superior reliability

• Transforms digital pathology by providing fast and uninterrupted workflow 40 1 Internal analysis 2 scanning up to 80 slides per hour Restructuring of Applied Science & Diabetes Care Positioning both businesses for future success

Roche Applied Science Roche Diabetes Care Secure long-term profitability by Drive innovation, growth & profitability adapting organisation to tougher via market leadership in focus areas market environment

• Keep focus in Sequencing, qPCR/NAP • Restructure R&D organization: and Custom Biotech/Reagents – Streamline blood glucose monitoring • Focus Microarray product line on portfolio Sequence Capture only – Invest in insulin delivery systems and continuous glucose monitoring • Streamline Cellular Analysis portfolio • Align R&D to support early innovation • Optimise M&D investments • Re-organise Marketing • One Global Operations structure

41 Key launches 2012

Area Product Market BA*

Labs cobas t 611 - Coagulation analyzer EU RPD BenchMark Special Stains - Tissue stainer WW  RTD VENTANA iScan HT - Digital tissue scanner EU, US  RTD

Point of cobas b 101 - Multi lipid and glucose analyzer EU RPD Instruments Care cobas b 123 POC - Blood gas analyzer US RPD /  Devices Diabetes 1 Care Accu-Chek Nano SmartView -Small, no-code bGM system US  RDC Accu-Chek Combo – Insulin pump & bG meter combined US  RDC Accu-Chek Mobile – Next generation strip free bGM system EU  RDC SOLO Micropump – Insulin pump and bG meter combined EU RDC

Oncology HE4 - Ovarian cancer US RPD ER – Breast cancer US RTD CINtec p16 Histology- Cervical cancer WW  RTD Tests/ GS GType Sequencing Primer Sets- Leukemia WW  RAS Assays Infectious CMV – Cytomegalovirus infections US  RMD Diseases CT/NG - Chlamydia and gonorrhoea infections US  RMD Metabolism Vitamin D - Vitamin D2 & D3 US RPD Achieve sales growth above the market 42 * Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics; RAS: Roche Applied Science; RTD: Roche Tissue Diagnostics; 1 blood glucose monitoring Group Alan Hippe Chief Financial Officer

43 HY 2012

Highlights

Optimizing value streams

Cash flow

44 HY 2012: Highlights

Core EPS +8%1 • Underlying business driving profit growth

Strong operating free cash flow • 7% growth at CER (+5% in CHF) • Receivables collection in Southern Europe improving

Productivity improvement initiatives • Actions implemented and on track

45 1 Constant Exchange Rates HY 2012: Group performance Core EPS growth +8%1 CHF m % Change HY 2012 HY 2011 CHF CER Sales 22,423 21,671 +3 +4 Core operating profit 8,641 8,251 +5 +7 as % of sales 38.5 38.1 Core net financial income -819 -792 +3 +2 Core tax rate in % 22.8 22.0 +0.8p Core net income 6,035 5,821 +4 +6 as % of sales 26.9 26.9 Attributable to Roche shareholders 5,922 5,697 +4 +7 Core EPS (CHF) 6.94 6.68 +4 +8 Operating free cash flow 7,170 6,856 +5 +7 % of sales 32.0 31.6 +0.4p Free cash flow -1,309 -967 -35 -14

46 1 CER=Constant Exchange Rates HY 2012: Group operating performance

HY 2012 vs. HY 2011 CER growth Major drivers Sales 4% Growth of Diagnostics Division, Herceptin, MabThera/Rituxan, Pegasys and Actemra

Royalties & other op. inc 8% Higher royalty and product disposal income Lower royalty (Boniva, Tamiflu, CellCept), 1 Cost of sales 0% COGS & PC : +2% manufacturing costs M & D 5% Investments mostly in China R & D 3% Stable R&D investments G & A Admin: +4% 11% IT cost phasing

Core operating profit 7%

+5% in CHF

47 CER=Constant Exchange Rates; 1 Period Costs HY 2012: Group core operating profit and margin Increase driven by Pharma Division

45.3% CHF m 43.9% % of sales 42.2% +2.1 %p1 38.5% 37.2% 38.1% (+1.4 %p) +1.0 % p1 (+0.4 % p)

9'159 +7 %1 (+5%) 1 8'251 8'188 +9 % 22.3% 21.9% (+7 %) 8'641 7'385 19.9% 7'889 -2.0 %p1 (-2.0 %p)

-5 %1 1'171 1'063 (-6 %) 2010 2011 2012 998

Roche Group Pharma Division Diagnostics Division 48 1 Constant Exchange Rates HY 2012

Highlights

Optimizing value streams

Cash flow

49 Optimizing value streams in 2012

Reallocate R&D resources into expanding pipeline • Focus portfolio (pRED) • Close Nutley Diagnostics business set-up • Reposition Applied Science • Address tougher environment in Diabetes Care

Cost structure • Finalize remaining part of Operational Excellence • Optimize IT Infrastructure to cope with business needs

Continuous focus on net working capital • Reducing receivables in Southern Europe

50 Optimizing value streams in 2012 Restructuring costs & savings

CHF m1 Restructuring costs Net Savings Reinvestments and P&L impact 1,440

1,196 410

289 Offsetting price 110 pressures in RDC and 49 810 investment in RAS

190 580* 430 Reinvestment 110 190 190 in pipeline 858 920 20 240 510 ~150 370

R&D & HY 2012 FY 2012+ Thereof Net P&L Diagnostics One-time costs cash out Savings savings reinvestment Pharma IT Diagnostics 51 1 at avg HY 2012 fx * 2013 CHF 500 m, 2014+ CHF +80 m From Core to IFRS operating profit Non-core items

HY 2011 HY 2012 CHF m Core operating profit8,251 8,641 +5% CHF / +7% CER

2,309 227 Intangibles amortisation1 95 Legal & environmental2 310 Intangibles impairment2

242 Dalcetrapib 239 Operational Excellence

791*

1 Restructuring Pharma R&D, Intangibles amortisation 270 1'196 Global issues 64 Diagnostics, IT Intangibles impairment 64 Operational Excellence 391

Operating profit 7,460 6,332 -15% CHF / -13% CER

52 1 includes Alliances & Business Combinations 2 excluding items covered in Restructuring / Dalcetrapib CER = Constant Exchange Rates * includes CHF 2 m Legal & environmental HY 2012

Highlights

Optimizing value streams

Cash flow

53 Strong operating free cash flow and margin

Group operating free cash flow (CHF bn) and margin

32.0%

26.1% 31.6% 28.2% +7% at CER 21.8% 7.17

6.78 6.86 6.43

4.81

HY 2008 HY 2009 HY 2010 HY 2011 HY 2012 54 CER=Constant Exchange Rates HY 2012: Operating free cash flow and margin 7% increase at CER

CHF m 38.5% 38.1% % of sales +0.4 %p1 31.6% 32.0% 31.6% (-0.4 %p) +0.8 % p1 26.1% (+0.4 % p)

+7 %1 +5 %1 6'856 (+5 %) 6'426 6'476 (+3 %) 7'170 6'123 15.8% 6'639 12.7% +3.0 %p1 10.6% (+3.1 %p)

+30 %1 557 617 (+29 %) 2010 2011 2012 793

Roche Group Pharma Division Diagnostics Division 55 1 at constant exchange rates (CER) HY 2012: Core net financial result Negative fx result offset by significantly lower interest expenses CHF m

0

-200

-400 -792 -792 Increase of 3% in CHF / 2% at CER-809 -809 -819 -858 -892 -872

Prior year: FX -600 gains Venezuela of CHF 42 m -66 +63 -10 -800 -34 -22 +42

-1000 Fx result, Equity Net interest & Bond Interest All other, 2011net gains debt securityredemption expense net 2012 income

56 CER=Constant Exchange Rates HY 2012: Group Core Tax Rate Higher profits in high tax countries in %

+0.5 +0.3

22.0 22.0 22.5 22.8

Higher profits in HY 2011high tax countries Other HY 2012

57 Core net financial result

Financial income (CHF bn) Net cash (debt) (CHF bn)

25 Liquid funds

15 0.68 0.48 0.37 5 0.30 0.24 -5

HY '08 HY '09 HY '10 HY '11 HY '12 -15

-25

-0.45 -35 Debt Net cash (debt) -45 -1.04 -1.06 -1.17 -55 -1.51 HY '08 HY '09 HY '10 HY '11 HY '12 Financing costs (CHF bn)

58 Core financial income and financing costs excl. net pension management Accounts receivables in Southern Europe Reduction of 24% vs. Dec 2011 due to Spain & Italy

Country credit rating June 2012 205 CC Greece 194 Dec 2011

207 BB Portugal 172

708 BBB+ Italy 805

423 A Spain 850

Southern -24% 1'543 European 2'021 Countries

- 500 1'000 1'500 2'000 2'500 EUR m

59 30 June 2012: Balance sheet Equity ratio at 20% in spite of significant restructuring provisions CHF bn 55.3 61.659.655.3 61.6 59.6

Cash and 11.3 9.2 16.2 marketable 8.3 18% 15% 18.0 Current 15.4 26% securities 15% liabilities 30% 28% Other 16.9 17.6 16.5 Net debt/ current 28% 30% 30% total assets: assets Non-current 30.9 29% 29.5 liabilities 29.1 50% 52% 50% Non-current 30.5 33.3 32.8 assets 54% 55% 24% 55% 20% 20% Equity 10.8 14.5 12.1 (Net assets) 30/06/1131/12/11 30/06/12 30/06/11 31/12/11 30/06/12 Assets Equity & liabilities 60 Currency impact on Swiss Franc results 2012 Negative in H1, positive in H2

CHF / USD average extrapolated average YTD 2012 YTD 2011 0.94 0.95 0.94 -2% 0.93 +2% +7% Assuming the 29 June 2012 exchange 0.92 +7% 0.91 0.89 rates remain stable until end of 2012, Monthly avg fx rates 0.88 2012 impact is expected to be (%p): 0.94 0.91 0.912012 0.91 0.94 0.96 0.97 Fx rate at 29 June 2012 Q1 HY Sep FY JFMAMJJASOND YTD

CHF / Sales -3 -1 +3 +3 EUR 1.29 Core 1.27 operating -2 +3 1.24 1.23 profit -6% -5% Core EPS -4 +1 -3% -3% 1.21 1.20 1.20 1.20 1.21 1.21 1.21 1.20 1.20 1.20 1.20

JFMAMJJASOND 61 Increasing shareholder value

P&L: increasing profitability • Core operating profit margin further increased (38.1% to 38.5% at HY 2012)

Delivering on pipeline • Perjeta successfully launched in US • T-DM1 pivotal study (EMILIA) presented at ASCO • Actemra head-to-head vs. Humira (ADACTA) presented at EULAR

Increasing cash generation • Operating Free Cash Flow increased by 7% (CER) to CHF 7.2 bn

62 CER=Constant Exchange Rates Outlook for 2012 confirmed

Sales growth (CER) Group & Pharma: low to mid-single digit Diagnostics: above market

Operational Excellence savings 2012+: CHF 2.4 bn*

Core EPS growth target High single-digit (CER)

Dividend outlook Continue attractive dividend policy

63 Barring unforeseen events; CER=Constant Exchange Rates; * vs. 2011: CHF 1.8 bn 64 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group HY 2012 results

Diagnostics

Foreign exchange rate information 65 Roche Development Pipeline Projects in Phase 1 Phase I (38 NMEs+2 AIs) Oncology Other Disease Areas RG7112 MDM2 ant solid & hem tumors RG7624 IL-17 MAb autoimmune diseases RG7116 HER3 MAb solid tumors CHU IL-6 MAb RA RG7155 CSF-1R MAb solid tumors RG7795 TLR7 agonist HBV RG7167 CIF/MEK inh solid tumors RG7667 - infectious diseases RG7204 Zelboraf + ipilimumab met. melanoma RG7685 GIP/GLP-1 dual ago type 2 diabetes RG7212 Tweak MAb oncology RG1662 GABRA5 NAM cogn. disorders RG7256 BRAF inh (2) BRAF mut melanoma RG7314 V1 receptor antag autism RG7304 Raf & MEK dual inh solid tumors RG7129 BACE inh Alzheimer’s RG7356 CD44 MAb solid tumors RG3645 Lucentis sust. deliv. AMD/RVO/DME RG7420 MEK inh solid tumors RG7421 MEK inh solid tumors RG7388 MDM2 ant solid & hem tumors RG7440 AKT inhibitor solid tumors RG7446 PD-L1 MAb solid tumors RG7450 Steap 1ADC prostate ca. RG7458 ADC ovarian ca. RG7593 CD22 ADC hem malignancies RG7594 anti-angiogenic solid tumors RG7596 ADC heme tumors New Molecular Entity (NME) RG7598 ADC multiple myeloma Additional Indication (AI) RG7599 ADC oncology RG7600 ADC oncology Oncology RG7601 Bcl-2 inh CLL and NHL Immunology RG7602 ChK1 inh solid tum & lymphoma Virology CardioMetabolism RG7604 PI3K inh solid tumors Neuroscience RG7636 ADC metastatic melanoma Ophthalmology RG7666 PI3k inh glioblastoma 2L RG7741 ChK1 inh(2) solid tumors RG-No Roche Genentech managed CHU ALK inhibitor NSCLC CHU Chugai managed CHU PI3K inh solid tumors CHU WT-1 peptide cancer vaccine 66 Status as of June 30, 2012 Roche Development Pipeline Projects in Phase 2, 3 and Registration Phase II Phase III Registration (23 NMEs + 12 Als) (9 NMEs + 25 Als) (2 NMEs + 7 Als)

RG1273 Perjeta (pertuzumab) HER2+ mBC 2nd line RG105 MabThera NHL sc formulation RG105 Rituxan NHL fast infusion RG1273 Perjeta (pertuzumab)HER2+ gastric cancer RG435 Avastin HER2+ BC adj RG4351 Avastin relapsed ovarian cancer RG3502 T-DM1 HER2+ EBC RG435 Avastin HER2-neg. BC adj RG597 1 Herceptin HER2+ BC sc form RG3616 Erivedge operable BCC RG435 Avastin NSCLC adj RG12732 Perjeta (pertuzumab) HER2+ mBC 1st line RG3638 onartuzumab (MetMAb) mBC RG435 Avastin high risk carcinoid RG36162 Erivedge advanced BCC RG3638 onartuzumab (MetMAb) mCRC 1L RG435 Avastin glioblastoma 1st line RG1052 MabThera ANCA assoc vascul RG3638 onartuzumab NSCLC non squamous RG435 Avastin mCRC TML RG1569 Actemra polyarticular JIA RG3638 onartuzumab NSCLC squamous RG435* Avastin ovarian cancer 1st line RG36453 Lucentis diabetic macular edema RG3638 onartuzumab glioblastoma RG435 Avastin ovarian cancer platinum resist. RG36453 Lucentis AMD 0.5 mg PRN RG7160 EGFR MAb solid tumors RG597 Herceptin HER2+ adj BC (2yrs) RG7204 Zelboraf papillary thyroid cancer RG1273 Perjeta (pertuzumab) HER2+ EBC RG7321 PI3K inh solid tumors RG1415* Tarceva NSCLC EGFR mut 1st line RG7422 PI3K/mTOR inh solid & hem tumors RG1415 Tarceva NSCLC adj 1 submitted in EU 2 approved in US, submitted in EU RG7414 EGFL7 MAb solid tumors RG3502 T-DM1 HER2+ pretreated mBC 3 submitted in US RG7597 HER3/EGFR m. epithelial tumors RG3502 T-DM1 HER2+ mBC 3rd l RG7686 glypican-3 MAb liver cancer RG3502 T-DM1 HER2+ mBC 1st l RG1569 Actemra systemic sclerosis RG3638 onartuzumab (MetMAb) mNSCLC RG7413 etrolizumab ulcerative colitis RG7159 obinutuzumab (GA101) CLL New Molecular Entity (NME) RG7415 rontalizumab SLE RG7159 obinutuzumab (GA101) iNHL relapsed Additional Indication (AI) RG7416 LT alpha MAb RA RG7159 obinutuzumab (GA101) DLBCL RG7449 M1 prime MAb asthma RG7159 obinutuzumab (GA101) iNHL front-line Oncology RG7128 mericitabine HCV RG1569 Actemra RA sc formulation Immunology RG7227 danoprevir HCV RG1569 Actemra early RA Virology RG7790 setrobuvir HCV RG1569 Actemra RA DMARD IR H2H CardioMetabolism Neuroscience RG4929 11 beta HSD inh metabolic diseases RG3637 lebrikizumab severe asthma Ophthalmology RG1512 P selectin MAb ACS/CVD RG3648 Xolair chronic idiopathic urticaria RG7418 oxLDL MAb sec prev CV events CHU Suvenyl enthesopathy RG7652 PCSK9 MAb metabolic diseases RG1439 aleglitazar CV risk reduction in T2D RG-No Roche Genentech managed CHU Chugai managed RG1450 gantenerumab Alzheimer’s CHU tofogliflozin (SGLT2) type 2 diabetes SST Seaside Therapeutics RG1577 MAO-B inh Alzheimer’s RG1594 ocrelizumab RMS RG105 MabThera is branded as RG1578 mGluR2 antag depression RG1594 ocrelizumab PPMS Rituxan in US and Japan RG7090 mGluR5 antag TRD RG1678 bitopertin schiz neg symptoms RG1569 Actemra is branded as RG7412 crenezumab Alzheimer‘s RG1678 bitopertin schiz subopt control RoActemra in EU SST arbaclofen autism (ASD) SST arbaclofen fragile X syndrome (FXS) RG7417 anti-factor D Fab geographic atrophy * approved in the EU 67 Status as of June 30, 2012 Changes to the development pipeline Since Q1 update on April 12, 2012

New to Phase I New to Phase II New to Phase III New to Registration 2 NMEs transitioned from Ph0 1 NME transitioned from Ph1 1 AI following decision to 1 AI filed in EU RG7666 PI3k inh glioblastoma 2L RG7652 PCSK9 MAb metabolic prepare for NDA submission RG105 MabThera ANCA associated RG7741 ChK1 inh(2) solid tumors diseases RG435 Avastin ovarian cancer vasculitis 1 AI following FPI platinum resistant Newly shown AI following NDA RG3638 onartuzumab NSCLC 1 NME opt-in opportunity submission squamous SST arbaclofen fragile X syndrome RG1569 Actemra polyarticular JIA RG3638 onartuzumab glioblastoma (FXS) 1 AI opt-in opportunity SST arbaclofen autism disorders (ASD)

Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration

Discontinuation (3NMEs) Discontinuation (1 NME & 1 AI) Following FDA complete RG7258 TSLPR MAb asthma RG1658 dalcetrapib CV risk response (1 AI) RG7334 PlGF MAb solid tumors reduction post ACS RG3626 Activase extended time RG4934 IL-17 MAb inflammatory RG1658 dalcetrapib CHD/CVD risk window AIS diseases reduction Out-licensing candidate (1NME) Decision not to file (2AIs) RG7185 CRTH2 antagonist asthma RG435 Avastin mBC 2nd line RG435 Avastin triple-neg BC adj

68 NME submissions and their additional indications Projects currently in Phase 2 and 3

EGFR MAb (RG7160) solid tumors

obinutuzumab(GA101) RG7159 NHL aggress. DLBCL

lebrikizumab (RG3637) asthma

mericitabine (RG7128) HCV

T-DM1 (RG3502) obinutuzumab(GA101) RG7159 danoprevir (RG7227) HER2+ mBC 1st line NHL indolent refractory (HCV protease inh)

bitopertin onartuzumab (MetMAb) mGluR5 antag (RG7090) (RG1678) schizophrenia# (RG3638) mNSCLC Tx resistant depression

obinutuzumab T-DM1 (RG3502) ocrelizumab (RG1594) aleglitazar (RG1439) anti-factor D Fab (RG7417) (GA101) RG7159) HER2+ advanced mBC PPMS and RMS CV risk reduction in T2D geographic atrophy CLL

2012 2013 2014 2015 2016

Unless stated otherwise, submissions are planned to occur in US and EU. Oncology Neuroscience Immunology Ophthalmology  indicates a submission which has occurred with regulatory action pending Virology NME # negative symptoms and sub-optimal control CardioMetabolism 69 Status as of June 30, 2012 Submissions of additional indications for existing products Projects currently in Phase 2 and 3

Avastin Avastin mCRC TML ovarian cancer platinum resist.

Herceptin Avastin sc formulation HER2+ relapsed ovarian cancer (US)

MabThera Avastin Perjeta st sc form (EU) ovarian cancer 1 line (US) HER2+ EBC

Tarceva (US) Avastin Perjeta st NSCLC EGFR mutation 1 line HER2+ BC adj HER2+ mBC 2ndline

Actemra Avastin Perjeta  st polyarticular JIA glioblastoma 1 line HER2+ gastric cancer

Actemra Herceptin Zelboraf RA DMARD IR H2H (EU) HER2+ BC adj 2 year papillary thyroid cancer

Actemra Tarceva Avastin sc formulation NSCLC adj (EU) HER2-neg BC adj

MabThera  Xolair (US) Avastin ANCA assoc vasculitis (EU) chronic idiopathic urticaria NSCLC adj

Lucentis  Actemra Tarceva Actemra AMD 0.5 mg PRN (US) early RA NSCLC adj (US) systemic sclerosis 2012 2013 2014 Post 2014

 indicates submission to Health Authorities has occurred. Oncology Neuroscience Immunology Ophthalmology Unless stated otherwise, submissions are planned to occur in US and EU. Virology CardioMetabolism 70 Status as of June 30, 2012 Major granted and pending approvals in 2012 Approved Pending approvals Erivedge (RG3616) Rituxan NHL faster infusion adv. basal cell ca US filed Dec 11 Perjeta (RG1273) Actemra st DMARD IR HER2+ mBC 1 line US filed Dec 2011 Actemra polyarticular JIA US filed June 2012 Lucentis diabetic macular edema US filed Oct 2011 Lucentis US AMD 0.5 mg PRN US filed Apr 2012

Zelboraf (RG7204) Avastin Relapsed ovarian cancer met. melanoma EU EU filed Aug 11 Perjeta (RG1273) HER2+ mBC 1st line EU Filed Dec 2011 Erivedge (RG3616) adv. basal cell ca EU Filed Nov 2011 Herceptin SC formulation EU filed Mar 2012 Oncology Neuroscience Actemra Immunology Ophthalmology polyarticularJIA Virology NME EU filed June 2012 CardioMetabolism MabThera ANCA associated vasculitis EU filed Apr 2012 71 Status as of June 30, 2012 Major Chugai granted and pending approvals in 2012

Approved Pending Approvals

Pulmozyme Actemra Improvement pulmonary sc formulation function in cystic fibrosis filed March 2012

Perjeta HER2+ mBC 1st line filed May 2012

Tarceva NSCLC EGFR mutation 1st line filed June 2012

Boniva/Bonviva osteoporosis filed July 2012

Oncology Neuroscience Immunology Ophthalmology Virology NME CardioMetabolism 72 Status as of June 30, 2012 We Innovate Healthcare

73 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group HY 2012 results

Diagnostics

Foreign exchange rate information 74 MabThera/Rituxan Development programmes

Oncology Immunology

Patient Front-line follicular non-Hodgkin’s Front-line diffuse large B-cell or ANCA-associated vasculitis population lymphoma follicular non-Hodgkin’s lymphoma

Phase III Phase IIIb SABRINA Phase II/III Phase/study RATE* Subcutaneous study RAVE* Faster infusion study Study being conducted ex-US # of patients N=405 N=450 N=197 Design • ARM A: MabThera IV plus chemotherapy • Prospective, open-label, single arm study • Non-inferiority efficacy and safety study (CHOP or CVP) of MabThera/Rituxan and glucocorticoids • ARM B: MabThera 1400mg sc plus versus conventional therapy chemotherapy (CHOP or CVP) (cyclophosphamide) Two-stage design: o Stage 1 (dose confirmation, N=127): PK primary endpoint o Stage 2 (N=280): Efficacy primary endpoint (ORR) Responders will continue on maintenance every 8 weeks over 24 months Primary • Pharmacokinetics, safety and efficacy • To determine the incidence of Grade 3 or • Induction of complete remission at 6 endpoint 4 infusion-related toxicities resulting from months, defined as a BVAS/WG of 0 and faster infusion of MabThera/Rituxan off glucocorticoid therapy Status • Stage 1 primary endpoint (PK noninferiority) • Enrolment completed Q4 2010 • Data presented at ACR 2009 met • Data presented at ASH 2011 • FDA approved use of Rituxan in WG and • Expect full stage 1 data presentation Q4 • Filed with the FDA in Q4 2011 MPA in Q2 2011 2012 • Submitted to EMA Q2 2012

*In collaboration with Biogen Idec; Subcutaneous MabThera : applies Enhanze technology, partnered with Halozyme CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; CVP = Cyclophosphamide, Vincristine and Prednisolone. 75 WG - Wegener's Granulomatosis, MPA - Microscopic Polyangiitis Avastin Ovarian cancer clinical development programme

Patient Front-line metastatic population ovarian cancer Phase/stud Phase III Phase III y GOG-0218 ICON7 # of N=1,873 N=1,528 patients Design • ARM A: Paclitaxel and carboplatin for 6 cycles plus 5 • ARM A: Paclitaxel and carboplatin for 6 cycles cycles of concurrent placebo followed by placebo alone • ARM B: Paclitaxel and carboplatin plus concurrent for up to 22 cycles (15 months) Avastin for 6 cycles followed by Avastin alone for up to • ARM B: Paclitaxel and carboplatin for 6 cycles plus 5 18 cycles (12 months) cycles of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months) • ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months) Avastin • 15 mg/kg q3 weeks • 7.5 mg/kg q3 weeks dose Primary • Progression-free survival • Progression-free survival endpoint Status • Study met its primary endpoint in Q1 2010 • Study met its primary endpoint Q3 2010 • Data presented at ASCO 2010 and 2011 • Data presented at ESMO 2010 and ASCO 2011 • Results published in NEJM December 2011 • Results published in NEJM December 2011

• EMA approval Q4 2011 • Re-evaluate FDA submission when final overall survival results from all phase III trials are available (expected 2013)

76 ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology. Avastin Ovarian cancer clinical development programme

Patient Relapsed platinum-sensitive Relapsed platinum-resistant population ovarian cancer ovarian cancer Phase III Phase III Phase/study OCEANS AURELIA # of patients N=484 N=361 Design • ARM A: Carboplatin, gemcitabine, and • ARM A: Paclitaxel, topotecan or liposomal concurrent placebo for 6 cycles, followed by doxorubicin placebo alone until disease progression • ARM B: Paclitaxel, topotecan or liposomal • ARM B: Carboplatin, gemcitabine, and doxorubicin plus Avastin concurrent Avastin for 6 cycles, followed by Avastin alone until disease progression.

Avastin dose • 15 mg/kg q3 weeks • 10 mg/kg q2 weeks or 15 mg/kg q3 weeks

Primary • Progression-free survival • Progression-free survival endpoint

Status • Study met its primary endpoint Q1 2011 • Study met its primary endpoint Q2 2012 • Data presented at ASCO 2011 • Data presented at ASCO 2012 • EMA submission Q3 2011 • EMA submission expected Q1 2013 • Re-evaluate FDA submission when final overall survival results from all phase III trials are available (expected 2013)

77 ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology. Avastin High risk carcinoid, brain and colorectal cancer development programmes

Patient High risk carcinoid Newly diagnosed glioblastoma Metastatic colorectal cancer population Phase III Phase III Phase III Phase/study ML18147 SWOG SO518 AVAglio TML # of patients N=424 N=920 N=810 Design • ARM A: Depot octreotide plus • ARM A: Concurrent radiation and •1st-line treatment with chemotherapy* interferon alpha temozolomide plus placebo; followed by plus Avastin • ARM B: Depot octreotide plus Avastin maintenance TMZ plus placebo for 6 • Once patients progress, they are cycles; then placebo until disease randomised to: progression • ARM A: Chemotherapy* alone • ARM B: Concurrent radiation and TMZ • ARM B: Chemotherapy* + Avastin plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then * Physician’s choice Avastin (15mg/kg q3 weeks) monotherapy until disease progression Avastin • 15 mg/kg q3 weeks • 10 mg/kg q2 weeks or 15 mg/kg q3 • 5 mg/kg q2 weeks or 7.5 mg/kg q3 dose weeks weeks Primary • Progression-free survival • Progression-free survival • Overall survival endpoint • Overall survival Status • Recruitment completed • Enrolment completed Q1 2011 • Primary end point met Q1 2012 • Expect data 2013 • Expect data 2012 • Data presented at ASCO 2012 • Expect global filing in 2012

78 Avastin Adjuvant clinical development programme

Patient Adjuvant Adjuvant population lung cancer breast cancer Phase III Phase III Phase III Phase III Phase/study ECOG 5103 BEATRICE BETH ECOG 1505 HER2-negative Triple-negative HER2-positive # of patients N=1,500 N=4,950 N=2,530 N=3,600 Design • ARM A: Cisplatin plus • ARM A: Anthracycline plus • ARM A: Anthracycline ± • COHORT 1: Docetaxel/ vinorelbine, docetaxel, cyclophosphamide (AC) taxane or taxane-based carboplatin plus Herceptin ± gemcitabine or pemetrexed followed by paclitaxel chemo alone Avastin • ARM B: Cisplatin plus • ARM B: AC plus Avastin • ARM B: Anthracycline ± • COHORT 2: Docetaxel plus vinorelbine, docetaxel, followed by paclitaxel plus taxane or taxane-based Herceptin ± Avastin, followed gemcitabine or pemetrexed Avastin chemo plus Avastin for 1 year by 5-Fluorouracil, Epirubicin, plus Avastin up to 12 months • ARM C: AC plus Avastin Cyclophosphamide followed by paclitaxel plus Avastin, followed by Avastin For both cohorts, patients up to 12 months receive Herceptin ± Avastin to complete one year of targeted therapy Avastin dose • 15 mg/kg q3 weeks • 15 mg/kg q3 weeks • Dosing equivalent to 5 mg/kg • 15 mg/kg q3 weeks weekly Primary • Overall survival • Disease-free survival • Disease-free survival • Disease-free survival endpoint Status • FPI Q3 2007 • FPI Q4 2007 • FPI Q4 2007 • FPI Q2 2008 • Recruitment ongoing • Enrolment completed Q2’11 • Enrolment completed Q4 2009 • Enrolment completed Q4 2010 • Expect data 2017-2018 • Expect data 2014 • Primary endpoint was not met • Expect data 2013 July 2012

79 Herceptin The standard of care for HER2+ early breast cancer

Patient Adjuvant HER2-positive Early-stage HER2-positive population breast cancer breast cancer

Phase III Phase III Phase/study HANNAH HERA Subcutaneous study

# of patients N=5,102 N=595

Design • ARM A: Herceptin for 12 months • ARM A: Chemotherapy* concurrent with • ARM B: Herceptin for 24 months Herceptin 600mg sc q3w for the first 8 • ARM C: Observation cycles • ARM B: Chemotherapy* concurrent with Herceptin IV for the first 8 cycles *Chemotherapy = docetaxel then 5-FU, epirubicin, and cyclophosphamide

Primary • Disease-free survival • Serum concentration endpoint • Pathologic complete response Status • Final 2-year versus 1-year analysis • Positive top-line data reported in October expected in 2012; event-driven 2011 • Data presented at EBCC 2012 • Filed in EU Q1 2012

Subcutaneous Herceptin : applies Enhanze technology, partnered with Halozyme 80 Perjeta First in a new class of HER dimerization inhibitors

Patient Adjuvant HER2+ breast First-line HER2-positive Second-line HER2-positive Advanced HER2-positive population cancer metastatic breast cancer metastatic breast cancer gastric cancer

Phase/ Phase III Phase III Phase II Phase IIa study APHINITY CLEOPATRA PHEREXA JOSHUA

# of patients N=3,806 N=808 N=450 N=30

Design • ARM A: Pertuzumab • ARM A: Pertuzumab • ARM A: Herceptin plus • ARM A: Pertuzumab (840mg loading, 420 q3w) (840mg loading, 420mg Xeloda (840mg loading, 420mg plus Herceptin for 52 weeks q3w) plus Herceptin and • ARM B: Pertuzumab plus q3w) plus Herceptin and plus chemotherapy (6-8 docetaxel Herceptin and Xeloda chemotherapy cycles) • ARM B: Placebo plus • ARM B: Placebo plus • ARM B: Placebo plus Herceptin and docetaxel Herceptin and Herceptin (52 weeks) plus chemotherapy chemotherapy (6-8 cycles) Primary • 3-year disease-free survival • Progression-free survival • Progression-free survival • Safety, efficacy endpoint Status • FPI Q4 2011 • Met primary endpoint July • FPI Q1 2010 • FPI Q4 2011 2011 • Data presented at SABCS 2011 • Submitted for FDA and EMA approval Q4 2011 • FDA granted approval Q2 2012

SABCS = San Antonio Breast Cancer Symposium. 81 Tarceva New approaches to treating lung cancer

First-line metastatic Patient Adjuvant non-small non-small cell lung cancer population cell lung cancer EGFR mutation-positive

Phase III Phase III Phase/study RADIANT EURTAC

N=974 # of patients N=174 (2:1 randomisation) Design • Following surgical resection ± adjuvant • ARM A: Tarceva chemotherapy: • ARM B: Chemotherapy (platinum-based • ARM A: Tarceva up to 2 years doublet) • ARM B: Placebo up to 2 years Primary • Disease-free survival • Progression-free survival endpoint • EGFR IHC and/or FISH-positive Status • Enrolment completed Q3 2010 • Study met its primary endpoint Q1 2011 • Expect final results H1 2013 • Data presented at ASCO 2011 • EU granted approval in Q3 2011 • Expect FDA sNDA submission in 2012

Tarceva is a registered trademark of OSI Pharmaceuticals, LLC, an affiliate of Astellas Pharma US, Inc. 82 Zelboraf A selective novel small molecule that inhibits mutant BRAF

• Phase II/III clinical trials

Previously untreated Previously treated Melanoma patients with Patient metastatic melanoma papillary thyroid cancer brain metastases population BRAF mutation positive BRAF mutation positive BRAF mutation positive Phase III Phase/study BRIM3 Phase II Phase II Global study

# of patients N=675 N=40 N=132

Design • ARM A: Zelboraf 960mg bid • Single ARM: Zelboraf • Single ARM: Zelboraf • ARM B: dacarbazine

Primary • Overall survival and progression-free • Best overall response rate • Overall Response Rate in endpoint survival the brain

Status • Study met both co-primary endpoints • FPI Q2 2011 • FPI Q3 2011 Q1 2011 • Data presented at ASCO 2011 • FDA granted approval Q3 2011 • Approved in EU Q1 2012 • Updated OS data presented at ASCO 2012

In collaboration with Plexxikon, a member of Daiichi Sankyo Group IRC = Independent Review Committee; RECIST = Response Evaluation Criteria in Solid Tumors. 83 Zelboraf A selective novel small molecule that inhibits mutant BRAF

• Phase I clinical trials

Melanoma patients with brain Patient Metastatic melanoma metastases population BRAF mutation positive BRAF mutation positive

Phase/study Phase Ib Phase I

# of patients N=20 N=20 Design • Single ARM: Zelboraf plus • Single ARM: Zelboraf ipilimumab

Primary •Safety •Safety endpoint Status • FPI Q4 2011 • FPI Q4 2010 • Recruitment completed • Abstract submitted to ESMO 2012

In collaboration with Plexxikon, a member of Daiichi Sankyo Group Combination study with ipilimumab is in collaboration with Bristol-Myers Squibb. 84 Erivedge (Vismodegib) A novel small molecule inhibitor of the hedgehog signaling pathway

Patient Advanced basal Operable basal population cell carcinoma cell carcinoma

Pivotal Phase II Phase/study Phase II ERIVANCE

# of patients N=104 N=74

Design • Single ARM: 150 mg GDC-0449 orally once daily • Single ARM: 150 mg GDC-0449 orally once daily until disease progression

Primary • Overall response rate • COHORT 1: Complete clearance (12 weeks Erivedge) endpoint • COHORT 2: Durable complete clearance (12 weeks Erivedge) • COHORT 3: Complete clearance (16 weeks Erivedge) Status • Positive results announced Q1 2011 • FPI Q4 2010 • Data presented at EADO June 2011, ECCO/ESMO • Cohort 1 data will be presented at Society for Sep 2011, EADV Oct 2011 Investigative Dermatology (May 2012) • EMA submission accepted Q4 2011 • FDA granted approval Q1 2012 • Data published NEJM June 2012

In collaboration with Curis 85 Actemra/RoActemra Interleukin 6 receptor inhibitor

Rheumatoid arthritis Patient Early moderate-to-severe Moderate-to-severe Moderate-to-severe DMARD inadequate population rheumatoid arthritis rheumatoid arthritis rheumatoid arthritis responders

Phase III Phase III Phase III Phase III Phase/study ADACTA SUMMACTA BREVACTA FUNCTION Head-to-head study Subcutaneous study Subcutaneous study

# of patients N=1,128 N=326 N=1,200 N=600 Design 104 week treatment 24 week treatment • Add-on to DMARD therapy • Add-on to DMARD therapy • ARM A: Actemra IV 8 mg/kg • ARM A: Actemra IV 8mg/kg • Weekly dosing for 104 • Dosing every two weeks for q4w plus pbo MTX q4w plus pbo Adalimumab weeks 104 weeks • ARM B: Actemra IV 8 mg/kg • ARM B: Adalimumab 40mg • ARM A: Actemra sc 162mg • ARM A: Actemra sc 162mg q4w plus MTX sc q2w plus pbo Actemra weekly plus placebo IV q4w q2w • ARM C: Actemra IV 4 mg/kg • ARM B: Actemra IV 8mg/kg • ARM B: Placebo sc q2w q4w plus MTX q4w plus placebo sc weekly • ARM D: MTX alone

Primary • DAS28 remission at 24 • DAS28 at 24 weeks • ACR 20 at week 24 • ACR 20 at week 24 endpoint weeks, 1 year and 2 years Status • FPI Q4 2009 • Trial met primary endpoint • Recruitment completed 2011 • Recruitment completed 2011 • Recruitment completed Q2 • Q1 2012 • Trial met primary endpoint • Expect data 2012 2011 • Data presented at EULAR Q2 2012 • Filing expected 2012 • Expect data 2012 2012 • Filing expected 2012 • Filing expected 2013 • Filing (EU) expected 2012

In collaboration with Chugai MTX = Methotrexate; DMARD = Disease-Modifying Anti-Rheumatic Drugs. 86 Actemra/RoActemra Interleukin 6 receptor inhibitor

Patient Polyarticular-course juvenile idiopathic Systemic sclerosis population arthritis

Phase II Phase III Phase/study faSScinate CHERISH # of patients N=86 N=188 Design Blinded 48-week treatment with weekly dosing: • Part I: All patients receive Actemra 8mg/kg or •ARM A: Actemra sc 162mg 10mg/kg (IV) q4w for 16 weeks •ARM B: Placebo sc • Part II: Patients with adequate response from Open-label weekly dosing at weeks 49 to 96: Part I will be randomized to receive: •Actemra sc 162mg ARM A: Actemra 8mg/kg or 10mg/kg (IV) q4w for up to 24 weeks + SOC* ARM B: Placebo + SOC*

• Part III: All patients receive Actemra 8mg/kg or 10mg/kg (IV) q4w for up to another 64 weeks

Primary • Change in modified Rodnan skin score (mRSS) • Proportion of patients with a JIA ACR30 flare by endpoint at week 24 week 40 relative to week 16 •Safety Status • FPI Q1 2012 • Study met primary endpoint in Q1 2012 • Expect data 2013 • Submitted to FDA and EMA Q2 2012

In collaboration with Chugai *Standard of care: non-steroidal anti-inflammatory drugs, corticosteroids, MTX 87 Xolair Evaluating potential in Chronic Idiopathic Urticaria, an IgE related disease

Patient Chronic Idiopathic Urticaria population Patients who remain symptomatic despite treatment*

Phase III Phase III Phase III Phase/study ASTERIA I ASTERIA II GLACIAL # of patients N=300 N=300 N=320 Design Add-on therapy to H1 anti- Add-on therapy to H1 anti- Add-on therapy to H1 anti- histamines histamines histamines, H2 blockers, and/or 24 week treatment period (q4- 12 week treatment period (q4- LTRA week) week) 24 week treatment period (q4- • ARM A: Xolair 300 mg •ARM A: Xolair 300 mg week) • ARM B: Xolair 150 mg •ARM B: Xolair 150 mg •ARM A: Xolair 300 mg • ARM C: Xolair 75 mg •ARM C: Xolair 75 mg •ARM B: Placebo • ARM D: Placebo •ARM D: Placebo Primary • Change from baseline in UAS7 • Change from baseline in UAS7 • Safety endpoint weekly itch score at Week 12 weekly itch score at Week 12

Status • Enrollment completed Q1 2012 • Enrollment completed Q4 2011 • Enrollment completed Q1 2012 • Data expected Q4 2012 • Data expected Q3 2012 • Data expected Q1 2013

In collaboration with Novartis 88 *Refractory to H1 anti-histamines, H2 blockers, and/or leukotriene receptor antagonists (LTRAs) at the time of randomisation. Lucentis Development programmes for wAMD and DME

Patient Neovascular (wet) age-related Diabetic macular edema population macular degeneration

Phase III Phase III Phase III Phase/study HARBOR RIDE RISE High dose study

# of patients N=1,110 N=382 N=378

Design • Randomised double-masked study • Randomised, sham-controlled study of monthly intravitreal injections of 0.5 comparing efficacy and safety of and 0.3 mg Lucentis for a total of 36 injections in patients with clinically intravitreal injections of 0.5 mg and significant macular edema with center involvement secondary to diabetes 2.0 mg Lucentis administered mellitus (Type I or Type II). monthly or PRN in patients with wet AMD Primary • Mean change in best corrected • Proportion of patients who gain ≥ 15 letters in BCVA score compared to endpoint visual acuity (BCVA) compared to baseline after 24 monthly injections (secondary endpoints include 36 month baseline at 12 months endpoint)

Status • 12 month data was presented at • Study met its primary endpoint Q1 • Study met its primary endpoint Q1 AAO meeting October 2011 2011 2011 • 0.5mg PRN sBLA filed with FDA in • Data presented at ADA 2011 • Data presented at ADA 2011 April 2012 • Submitted for FDA approval October • Submitted for FDA approval October 2011 2011

Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. 89 ADA – American Diabetes Association, AAO = American Academy of Opthalmology Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group HY 2012 results

Diagnostics

Foreign exchange rate information 90 Trastuzumab emtansine (T-DM, RG3502) Evaluating new treatment options in HER2+ breast cancer

Patients who have Pretreated Previously untreated Patient Neoadjuvant/ Adjuvant progressed on HER2 targeted HER2 pos. metastatic breast HER2 pos. metastatic breast population treatment cancer1 cancer Phase II Phase III Phase III Phase III Phase/ study Cardiac safety study TH3RESA EMILIA MARIANNE

# of patients N=135 N=795 N=991 N=1,092

Design • Single ARM: T-DM1 • ARM A: T-DM1 3.6mg/kg • ARM A: T-DM1 3.6mg/kg • ARM A: Herceptin plus 3.6mg/kg q3w administered q3w q3w taxane immediately following • ARM B: physician’s choice • ARM B: Xeloda plus lapatinib • ARM B: T-DM1 3.6mg/kg completion of anthracycline q3w plus pertuzumab chemotherapy • ARM C: T-DM1 3.6 mg/kg q3w plus placebo

Primary • Cardiac event rate • ORR and Overall survival Co-primary endpoints: • Progression-free survival endpoint • Safety • Progression-free survival assessed by IRF (PFS) • Overall survival

Status • Completed enrollment Q2 • FPI Q3 2011 • Positive top-line data reported • FPI Q3 2010 2011 Q1 2012 • Recruitment completed Q2 • Interim data presented at • Data presented at ASCO 2012 2012 ASCO 2012 • Filing planned in 2012

In collaboration with ImmunoGen ASCO = American Society of Clinical Oncology 1 Patients must have received prior treatment which included both: a taxane, alone or in combination with another agent, and trastuzumab in the adjuvant, locally advanced, or metastatic setting. 91 Obinutuzumab (GA101, RG7159) Type II, glycoengineered anti-CD20 monoclonal antibody

• Phase III clinical trials

Front-line Indolent chronic lymphocytic non-Hodgkin’s Front-line indolent Patient Diffuse large B-cell leukaemia lymphoma non-Hodgkin’s population lymphoma (DLBCL) Patients with MabThera/Rituxan lymphoma comorbidities refractory Phase III Phase III Phase III Phase III Phase/study CLL11 GADOLIN GALLIUM GOYA

# of patients N=780 N=360 N=1,400 N=1,400

Design • ARM A: GA101 1000mg • ARM A: GA101 1000mg • ARM A: GA101 1000mg • ARM A: GA101 1000mg IV plus chlorambucil IV plus Bendamustine IV plus chemotherapy IV plus CHOP • ARM B: • ARM B: Bendamustine followed by GA101 • ARM B: MabThera/Rituxan plus maintenance MabThera/Rituxan plus chlorambucil • ARM B: CHOP • ARM C: Chlorambucil MabThera/Rituxan plus alone chemotherpy followed by MabThera/Rituxan maintenance Primary • Progression-free survival • Progression-free survival • Progression-free survival • Progression-free survival endpoint Status • FPI Q4 2009 • FPI Q2 2010 • FPI Q3 2011 • FPI Q3 2011 • Recruitment completed • Expect data 2015 Q2 2012 • Expect data 2013

In collaboration with Biogen Idec CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisone 92 Obinutuzumab (GA101, RG7159) Type II, glycoengineered anti-CD20 monoclonal antibody

• Phase I/II clinical trials

Front-line or relapsed Relapsed or refractory Patient Relapsed indolent non-Hodgkin’s non-Hodgkin’s lymphoma or chronic population indolent non-Hodgkin’s lymphoma lymphoma (NHL) lymphocytic leukaemia (CLL) Phase Ib Phase I/II Phase I/II Phase/study GAUDI GAUSS GAUGUIN # of patients N=136 N=202 N=133 Design • Cohort A: GA101 plus fludarabine Phase I portion Phase I portion: + cyclophosphamide (extended treatment for 2 years): • Single agent: GA101 • Cohort B: GA101 plus CHOP • Single agent: GA101 • Cohort C: GA101 plus Phase II portion: bendamustine Phase II portion • Single agent: GA101 (extended treatment for 2 years): • ARM A: MabThera/Rituxan • ARM B: GA101 Primary • Safety • Overall response rate • Phase I: Incidence of dose-limiting toxicity endpoint • Phase II: Overall best response rate Status • FPI Q1 2009 Phase I portion: Phase I portion: • Data presented at ASH 2011 • Initiated Q1 2008 • Initiated Q3 2007 • Data presented at ASH 2009 • Updated Phase I NHL and CLL data Phase II portion: presented at ASH 2009 • FPI Q3 2009 Phase II portion: • Enrolment completed Q3 2010 • All cohorts completed enrolment by Q4 • Data presented at ASH 2011 2009 • Data presented at ICML/EHA 2011 In collaboration with Biogen Idec CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; 93 ASH = American Society of Hematology; EHA = European Hematology Association. Onartuzumab (MetMAb, RG3638) Anti-Met monovalent antibody that inhibits HGF-mediated activation

2nd- and 3rd-line 1st and 2nd-line Patient 1st-line metastatic Met-positive metastatic triple negative metastatic population colorectal cancer NSCLC breast cancer Phase III Phase Phase II Phase II MetLung # of patients N=480 N=180 N=188 Design • ARM A: Tarceva plus • ARM A: Avastin and • ARM A: FOLFOX plus onartuzumab paclitaxel plus Avastin plus • ARM B: Tarceva plus onartuzumab onartuzumab placebo • ARM B: Avastin and • ARM B: FOLFOX plus paclitaxel plus placebo Avastin plus placebo • ARM C: Paclitaxel plus onartuzumab Primary • Overall survival • Progression–free survival • Progression–free endpoint survival in ITT • Progression-free survival in pre-specified Met- positive patients Status • FPI Q1 2012 • FPI Q1 2011 • FPI Q3 2011 • Enrollment completed July 2012 • Expect data H2 2013 94 Onartuzumab (MetMAb, RG3638) Anti-Met monovalent antibody that inhibits HGF-mediated activation

Patient Avastin-naïve recurrent 1st line non-squamous NSCLC 1st line squamous NSCLC population glioblastoma Phase Phase II Phase II Phase II

# of patients N=260 N=110 N=120

Design Cohort 1 • Arm A: Onartuzumab + paclitaxel • Arm A: Onartuzumab + Avastin •Arm A: Onartuzumab + Avastin + + platinum-based chemo (cisplatin • Arm B: Placebo + Avastin paclitaxel + platinum-based chemo or carboplatin) • Arm C: Onartuzumab +Placebo (cisplatin or carboplatin) •Arm B: Placebo + Avastin + • Arm B: Placebo + paclitaxel + paclitaxel + platinum-based chemo platinum-based chemo (cisplatin or (cisplatin or carboplatin) Cohort 2 carboplatin) •Arm A: Onartuzumab + pemetrexed + platinum-based chemo (cisplatin or carboplatin) Arm B: Placebo + pemetrexed + platinum-based chemo (cisplatin or carboplatin)

Primary • Progression-Free Survival in the ITT • Progression-Free Survival in the ITT • Progression-Free Survival in the ITT endpoint population population population • Progression-Free Survival in Met- • Progression-Free Survival in Met- • Progression-Free Survival in Met- positive population positive population positive population Status • FPI Q2 2012 • FPI Q2 2012 • FPI July 2012

95 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 • Phase III clinical trials

Severe uncontrolled adult asthma Adult patients whose Adult patients whose Patient asthma is uncontrolled with inhaled asthma is uncontrolled with inhaled population corticosteroids and a second controller corticosteroids and a second controller medication medication Phase III Phase III Phase/study LUTE VERSE # of patients N=1,400 N=1,400 Design Subcutaneous lebrikizumab q4w on top of SOC for 52 Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks followed by 52 week extension on lebrikizumab weeks followed by 52 week extension on lebrikizumab for a total of 104 weeks, with a 24 week safety follow- for a total of 104 weeks, with a 24 week safety follow- up up •ARM A: Lebrikizumab highest dose •ARM A: Lebrikizumab highest dose •ARM B: Lebrikizumab middle dose •ARM B: Lebrikizumab middle dose •ARM C: Lebrikizumab lowest dose •ARM C: Lebrikizumab lowest dose •ARM D: Placebo •ARM D: Placebo Patients will be tested for periostin level Patients will be tested for periostin level Primary • Rate of asthma exacerbations during the 52-week • Rate of asthma exacerbations during the 52-week endpoint placebo-controlled period placebo-controlled period Status • FPI Q1 2012 • FPI Q1 2012 96 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

• Phase II clinical trials

Severe uncontrolled adult asthma

Patient Adult patients who are inadequately Adult patients who population controlled on inhaled corticosteroids are not taking inhaled corticosteroids

Phase II Phase II Phase/study MILLY MOLLY Proof of concept study Dose-ranging study # of patients N=218 N=212 Design • ARM A: Lebrikizumab • ARM A: Lebrikizumab Dose level A • ARM B: Placebo • ARM B: Lebrikizumab Dose level B • ARM C: Lebrikizumab Dose level C • ARM D: Placebo Primary • Change in FEV1 • Change in FEV1 endpoint Status • Data published Corren et al. 2011 NEJM (and • FPI Q4 2009 NEJM correspondence Dec 2011) • Topline data: Q1 2011 • Two abstracts accepted at ATS 2012; i) PD • Publication planned Q4 2012 marker data and ii) post hoc 32 week analysis of exacerbation rates 97 Aleglitazar (RG1439) A balanced PPAR co-agonist - potential to reduce cardiovascular events in type 2 diabetes patients

Type 2 diabetes Patient ACS patients with Patients with moderate and mild population Type 2 diabetes renal impairment Phase II Phase III Phase/study AleNEPHRO AleCARDIO Renal function study Cardiovascular outcomes study # of patients N=300 N=7,229 Design • 52 week treatment duration: • At least 2.5 years treatment period and until • ARM A: Aleglitazar (150 μg) 950 events have occurred • ARM B: Pioglitazone (45 mg) • ARM A: Aleglitazar (150 μg) on top of SOC • ARM B: Placebo on top of SOC Primary • Relative change from baseline in glomerular • Reduction in cardiovascular mortality, non- endpoint filtration rate at 60 weeks fatal myocardial infarction and stroke (MACE)

Status • Enrollment completed Q2 2011 • FPI Q1 2010 • Expect data H2 2012 • Enrollment completed Q2 2012

ACS = Acute Coronary Syndrome; SOC = standard of care. 98 Bitopertin (GlyT-1, RG1678) A small molecule first-in-class glycin reuptake inhibitor (GRI)

Acute Patient Persistent, predominant exacerbation of Sub-optimally controlled symptoms of schizophrenia population negative symptoms of schizophrenia schizophrenia

Phase II Phase III Phase III Phase III Phase III Phase III Phase III Phase/study Proof of concept NIGHTLYTE MOONLYTE TWILYTE SUNLYTE DAYLYTE FLASHLYTE study

# of N=300 N=600 N=600 N=600 N=630 N=630 N=630 patients Design • 4-week • Add-on therapy • Add-on therapy • Add-on therapy • Add-on therapy • Add-on therapy • Add-on therapy treatment period to anti-psychotics to anti-psychotics to anti-psychotics to anti-psychotics to anti-psychotics to anti-psychotics •ARM A: • 52-week • 52-week • 52-week • 52-week • 52-week • 52-week RG1678 daily treatment period treatment period treatment period treatment period treatment period treatment period (10 mg) •ARM A: •ARM A: •ARM A: •ARM A: •ARM A: •ARM A: •ARM B: RG1678 daily RG1678 daily RG1678 daily RG1678 (10 RG1678 (5 mg) RG1678 (10 RG1678 daily (10 mg) (10 mg) (5 mg) mg) •ARM B: mg) (30 mg) •ARM B: •ARM B: •ARM B: •ARM B: RG1678 (10 •ARM B: •ARM C: RG1678 daily RG1678 daily RG1678 daily RG1678 (20 mg) RG1678 (20 Olanzapine (20 mg) (20 mg) (10 mg) mg) •ARM C: mg) •ARM D: •ARM C: •ARM C: •ARM C: •ARM C: Placebo •ARM C: Placebo Placebo Placebo Placebo Placebo Placebo

Primary • PANSS total • PANSS positive • PANSS positive • PANSS positive • PANSS negative • PANSS negative • PANSS negative endpoint symptom factor symptom factor symptom factor symptom factor symptom factor symptom factor symptom factor at week 4 at week 12 at week 12 at week 12 at week 24 at week 24 at week 24

Status • FPI Q1 2011 • FPI Q4 2010 • FPI Q4 2010 • FPI Q4 2010 • FPI Q4 2010 • FPI Q4 2010 • FPI Q4 2010

PANSS = Positive and Negative Syndrome Scale 99 Ocrelizumab (RG1594) 2nd generation anti-CD20 monoclonal antibody

Patient Primary progressive Relapsing multiple sclerosis (RMS) population multiple sclerosis (PPMS)

Phase/stud Phase III Phase III Phase III y OPERA I OPERA II ORATORIO # of N=800 N=800 N=630 patients Design • 96-week treatment period: • 96-week treatment period: • 120-week treatment period: • ARM A: Ocrelizumab 2x • ARM A: Ocrelizumab 2x • ARM A: Ocrelizumab 2x 300 mg IV followed by 600 300 mg IV followed by 600 300 mg IV every 24 weeks mg IV every 24 weeks mg IV every 24 weeks • ARM B: Placebo • ARM B: Interferon β-1a • ARM B: Interferon β-1a

Primary • Annualized relapse rate at • Annualized relapse rate at 96 • Sustained disability endpoint 96 weeks versus Rebif weeks versus Rebif progression versus placebo by Expanded Disability Status Scale (EDSS) Status • FPI Q3 2011 • FPI Q3 2011 • FPI Q1 2011

100 Mericitabine (RG7128) Nucleoside NS5B polymerase inhibitor

Treatment-naive and failure Treatment-naive and failure Patient chronic hepatitis C chronic hepatitis C population Genotype 1 and 4 Genotype 1 and 4 Phase IIb Phase IIb Phase/study DYNAMO 2 DYNAMO 1* Longer duration study N=100 # of patients N= 168

Design • ARM A: Boceprevir + mericitabine (1000 mg BID) + • ARM A: Telaprevir + mericitabine (1000 mg BID) + Pegasys Pegasys and Copegus for 24 weeks and Copegus for 12 weeks, followed by + mericitabine (1000 • ARM B: Boceprevir + mericitabine (1000 mg BID) + mg BID) + Pegasys and Copegus for 12 weeks Pegasys and Copegus for 24 weeks followed by • ARM B: Telaprevir + mericitabine (1000 mg BID) + Pegasys boceprevir+Pegasys and Copegus for 24 weeks and Copegus for 12 weeks, followed by + mericitabine (1000 • ARM C : Boceprevir+Pegasys and Copegus for 48 weeks mg BID) + Pegasys and Copegus for 12 weeks, followed by Pegasys and Copegus for 24 weeks • ARM C : Telaprevir + mericitabine (1000 mg BID) + Pegasys and Copegus for 12 weeks, followed by Pegasys and Copegus for 36 weeks • ARM D: Telaprevir + Pegasys and Copegus for 12 weeks, followed by Pegasys and Copegus for 36 weeks Primary • Sustained virological response (SVR) • Sustained virological response (SVR) endpoint Status • FPI Q4 2011 • FPI Q4 2011

RG7128 licensed from Pharmasset, now part of Gilead 101 * In collaboration with Merck Mericitabine (RG7128) Nucleoside NS5B polymerase inhibitor

Hepatitis C patients Patient population Treatment-naïve or null-responders to interferon-based treatment

Phase II Phase/study ANNAPURNA

# of patients N=180

Design • ARM A: ARM A: GT1a including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine • ARM B: ARM A: GT1a including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine • ARM C: GT1a including setrobuvir, danoprevir, ritonavir and ribavirin • ARM D: GT1b including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine • ARM E: GT1b including setrobuvir, danoprevir, ritonavir and ribavirin

Primary endpoint • Sustained virological response at week 12

Status • FPI Q2 2012

RG7128 licensed from Pharmasset, now part of Gilead 102 Danoprevir (RG7227) HCV protease inhibitor

Patient Treatment-experienced population chronic hepatitis C patients*

Phase IIb Phase Matterhorn Boosted Danoprevir in Triple, Quad and Interferon-free combinations

# of patients N=381 Design Danoprevir boosted by low dose ritonavir in IFN-free, triple and QUAD Cohort A: partial responders: •ARM A1: Danoprevir 100 mg bid+ Ritonavir 100mg bid+ mericitabine 1000 mg bid + Copegus for 24 weeks •ARM A2: Danoprevir 100 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 24 weeks •ARM A3: Danoprevir 100 mg bid + Ritonavir 100mg bid + mericitabine 1000 mg bid + Pegasys + Copegus for 24 weeks Cohort B: null responders: •ARM B1: Danoprevir 100 mg bid + Ritonavir 100mg bid + mericitabine 1000 mg bid + Copegus for 24 weeks •ARM B2: Danoprevir 100 mg bid + Ritonavir 100mg bid+ mericitabine 1000 mg bid + Pegasys + Copegus for 24 weeks •ARM B3: Danoprevir 100 mg bid+ Ritonavir 100mg bid + mericitabine 1000 mg bid + Pegasys + Copegus for 24 weeks, followed by 24 weeks Pegasys + Copegus

Primary • Sustained virological response 24 weeks after the end of study treatment endpoint Status • Recruitment completed Q3 2011 • Preliminary data submitted to AASLD 2012

RG7128 licensed from Pharmasset, now part of Gilead 103 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group HY 2012 results

Diagnostics

Foreign exchange rate information 104 Oncology development programmes Small molecules

Apoptosis MAPK signaling MDM2 (4) MDM2 antagonist BRAF inhibitor(2) MEK inhibitor Raf/MEK inhibitor Molecule antagonist (RG7112) (RG7256) (CIF, RG7167) (CKI27, RG7304) (RG7388) Hematologic Solid and Patient Advanced solid BRAF mutated neoplasms hematological Solid tumors Solid tumors population tumors solid tumors (Leukaemia) tumors Phase Phase I Phase I Phase I Phase I Phase I Phase I # of patients N=105 N=90 N=100 N=100 N=144 N=52 Design • Multiple • Multiple • Multiple • Multiple • Dose-escalation, • Dose-escalation ascending ascending dose- ascending dose- ascending dose followed by to MTD dose- escalation study escalation study study with expansion into 4 escalation extension cohorts in study cohorts specific indications Status • Study • Initiated Q2 2008 • FPI Q4 2011 • FPI Q3 2010 • Initiated Q2 2008 • Initiated October completed Q2 • Preliminary • Recruitment • Phase I study Q4 2008 2011 results presented completed Q4 completed • Phase I study • Expect to at ASH 2010 and 2011 recruitment into Stopped initiate Phase 2011 expansion enrolment in Q4 Ib studies in Q2 • Expect to initiate cohorts end of 2010 2012 Phase Ib studies 2011 in Q2 2012 Collaborator Plexxikon Chugai Chugai 105 Plexxikon Inc., a member of Daiichi Sankyo Group Oncology development programmes Monoclonal antibodies

Anti-glypican-3 MAb Anti-CD44 MAb Molecule (GC33, RG7686) (RG7356)

Patient Metastatic liver cancer 2L metastatic liver cancer Solid tumors population (hepatocellular carcinoma) (hepatocellular carcinoma)

Phase Phase Ib Phase II Phase I # of patients N= 40-50 N=156 N=50-70 Design • Study US Monotherapy Adaptive design study • Multiple ascending dose study • Study Japan Monotherapy Double blind randomized 2:1 with extension and imaging • Combo with SOC dose RG7686:placebo arm escalation study Patients are stratified according to the level of GPC-3 expression in tumor

Primary • Safety and tolerability • Progression-free survival • Safety (MTD), PK, PD, endpoint preliminary activity Status • FPI Q4 2008 • FPI Q1 2012 • FPI Q2 2011 • Dose Escalation completed for US and Japan monotherapy studies. CSRs drafting is ongoing Collaborator Chugai 106 SOC – standard of care Oncology development programmes Monoclonal antibodies (continued)

Anti-TWEAK MAb GE-huMAb HER3 CSF-1R huMAb Molecule (RG7212) (RG7116) (RG7155)

Patient Solid tumors Solid tumors Solid tumors population

Phase Phase I Phase I Phase I # of patients N=100 N=105 N-95 Design • Multiple ascending dose • Multiple ascending dose • •Multiple ascending dose study with extension study with extension study +/- paclitaxel with cohorts cohorts and imaging sub- extension cohorts study • Combination arms with HER1-targeted therapies (erlotinib, cetuximab) Primary • Safety, PK, PD • Safety, PK • Safety, PK, PD & clinical endpoint activity

Status • FPI Q3 2011 • FPI Q4 2011 • FPI Q4 2011

107 GA201 (RG7160) Glycoengineered enhanced ADCC/anti-EGFR monoclonal antibody

Head and neck Patient 1st-line metastatic 2nd-line metastatic squamous cell population non-small cell lung cancer colorectal cancer carcinoma Phase I Phase Mechanism of action Phase Ib/II Phase II study # of patients N=45 N=160 N=160 Design • ARM A: GA201 Treated until disease progression: Treated until disease progression: • ARM B: Cetuximab Squamous KRAS Wild Type .ARM A: GA201 plus cisplatin and .ARM A: GA201 plus FOLFIRI gemcitabine .ARM B: Cetuximab plus FOLFIRI .ARM B: Cisplatin and gemcitabine KRAS Mutant Non-Squamous .ARM A: GA201 plus FOLFIRI .ARM A: GA201 plus cisplatin and .ARM B: FOLFIRI alone pemetrexed .ARM B: Cisplatin and pemetrexed Primary • Pharmacodynamics • Part 1 – Safety •PFS endpoint • Part 2 – PFS Status • Recruitment • Non-Squamous Part 2 accrual complete 1Q • FPI Q2 2011 completed Q1 2012 2012. • Recruitment completed July 2012 • Data presented at • Data from Part 1 Non-Sq. presented at • Design presented at ASCO 2012 ASCO 2012 ASCO 2012 • Squamous Part 1 halted and to be 108 investigated with new study Metabolic development programmes

P-selectin huMAb 11 Beta HSD inhibitor GLP-1/GIP dual agonist Molecule (RG1512) (RG4929) (MAR701, RG7685)

Prevention of saphenous Acute Coronary vein graft disease Syndrome (ACS) Patient Patients undergoing Patients undergoing Metabolic diseases Type 2 diabetes population coronary artery bypass Percutaneous Coronary graft (CABG) surgery Intervention (PCI) Phase II Phase/study Phase II Phase II Phase I Proof of mechanism study

# of patients N=384 N=516 N=80 N=50

Design 32-week treatment period Single infusion 12-week treatment • Multiple ascending dose •ARM A: RG1512 (20 •ARM A: RG1512 (5 •ARM A: RG4929 (200 (MAD) study mg/kg) mg/kg) mg) •ARM B: Placebo •ARM B: RG1512 (20 •ARM B: Placebo mg/kg) •ARM C: Placebo Primary •Sapheneous vein graft re- •Procedural damage •Liver fat content (MRS) • Safety, PK Endpoint occlusion (troponin)

Status • FPI Q4 2010 • FPI Q2 2011 • FPI Q1 2011 • Study completed • Expect data H2 2012 • Follow-up study in preparation Marcadia Biotech, Inc. Collaborator Genmab acquisition 109 Neuroscience development programmes

• Phase I/II studies

Monoamine oxidase type B Gantenerumab BACE inhibitor Molecule (MAO-B) inhibitor (Anti-Αβ, RG1450) (RG7129) (RG1577, EVT-302)

Patient Prodromal Alzheimer’s Disease Alzheimer’s Disease Alzheimer’s Disease population Phase II Phase/study Phase I Phase I SCarlet RoAD

# of patients N=770 N=36 N=6

Design 104-week subcutaneous treatment period • Single ascending dose study, • Mass balance study •ARM A: RG1450 (225 mg) incl. food effect •ARM B: RG1450 (105 mg) •ARM C: Placebo

Primary • Change in CDR-SOB at 2 years • Safety • Metabolic profile endpoint • Substudy: change in brain amyloid by PET • Route of elimination at 2 years

Status • FPI Q4 2010 • FPI Q3 2011 • FPI Q2 2012 • Ph I PET data published in Arch. Neur. Q4 • Enrollment completed Q1 2012 2011

Collaborator Morphosys Siena Biotech Evotec

CDR-SOB = Clinical Dementia Rating scale Sum of Boxes 110 Neuroscience development programmes

• Phase II studies

Metabotropic glutamate receptor pathway

mGluR2 antagonist mGluR5 antagonist Molecule (RG1578) (RG7090)

Patient Adjunctive Treatment of Adjunctive Treatment of Fragile X Syndrome population Major Depressive Disorder Major Depressive Disorder

Phase/study Phase II Phase II Phase II

# of patients N=480 N=300 N=180 Design • ARM A: RG1578 5 mg . ARM A: RG7090 0.5 mg . ARM A: RG7090 0.5 mg • ARM B: RG1578 15 mg . ARM B: RG7090 1.5 mg . ARM B: RG7090 1.5 mg • ARM C: RG1578 30 mg . ARM C: Matching Placebo . ARM C : Matching • ARM D: Matching Placebo Placebo

Primary • Efficacy - Montgomery • Efficacy - Montgomery • Efficacy, Safety and endpoint Asberg Depression Rating Asberg Depression Rating Tolerability Scale Scale

Status • Recruitment ongoing • Recruitment ongoing • Recruitment ongoing • Expect data H2 2013 • Expect data H2 2013 • Expect data H2 2013

111 Neuroscience development programmes

• Phase I studies

V1 receptor GABRA5 negative allosteric modulator (NAM) Molecule antagonist (RG1662) (RG7314)

Patient Down Syndrome Autism population

Phase Phase I Phase I Phase Ib Phase I

# of patients N=90 N=32 N=23 N=45

Design • Single ascending • Multiple ascending •Multi-center, • SAD/MAD umbrella dose study/PET in dose study in healthy Randomized, Double- protocol including healthy volunteers volunteers blind, Placebo- food effect controlled, Multiple Dose Study in Individuals With Down Syndrom

Primary • Food effect, Brain • Safety • Safety, tolerability • Safety, Tolerability endpoint Receptor Occupancy, Safety

Status • FPI Q1 2010 • FPI Q4 2010 • FPI Q4 2011 • FPI Q3 2010 • Enrollment completed • Enrollment completed Q3 2011 112 Virology development programme

Setrobuvir Molecule (RG7790) Patient Chronic Hepatitis C population Phase Phase II # of patients N= 283 Design • ARM A: Setrobuvir/placebo (200 mg bid) + Pegasys + Copegus for 28-48 weeks* in naïve patients • ARM B: Setrobuvir/placebo (200 mg bid) + Pegasys + Copegus for 48 weeks in treatment experienced patients (paritial responders & relapsers) • ARM C: Setrobuvir (200 mg bid) + Pegasys + Copegus for 48 weeks in treatment experienced patients (null responders)

* Response guided treatment

Primary • Sustained virological response 24 weeks after the end of study treatment endpoint Status • FPI Q1 2011 • Recruitment completed Q3 2011

Collaborator Anadys Pharmaceuticals Inc. acquisition

Being investigated in Phase II in combination with Danoprevir and Mericitabine (see Mericitabine). 113 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group HY 2012 results

Diagnostics

Foreign exchange rate information 114 Oncology development programmes

Angiogenic signaling Anti-angiogenic Anti-EGFL7 MAb Molecule (RG7594) (RG7414) Patient First-line metastatic First-line metastatic Advanced solid tumors Advanced solid tumors population non-small cell lung cancer colorectal cancer Phase II Phase II Phase Phase Ia/Ib Phase Ib NILE CONGO # of patients N=~54 N=~64 N=100 N=120 Design • Dose escalation study • ARM A: Anti-EGFL7 plus • Anti-EGFL7 plus Avastin • ARM A: Anti-EGFL7 plus • Phase Ib portion in Avastin plus carbo/tax vs Avastin Avastin plus FOLFOX combination with Avastin • ARM B: Anti-EGFL7 plus plus carbo/tax • ARM B: Avastin plus Avastin and paclitaxel FOLFOX • RCC expansion/Biopsy Cohort: Anti-EGFL7 plus Avastin • Flat dose Cohort: Anti- EGFL7 plus Avastin Primary • Safety/PK • Safety/PK • PFS • PFS endpoint Status • FPI Q2 2010 • FPI Q1 2010 • FPI Q2 2011 • FPI Q4 2011 • Data presented at ASCO 2011

115 Oncology development programmes

Growth factor signaling Anti-HER3 EGFR DAF MAb Molecule (RG7597) KRAS wild-type Patient Metastatic epithelial Metastatic/recurrent metastatic colorectal population tumors SCCHN cancer Phase II Phase Phase I Phase II MEHGAN # of patients N=66 N=110 N=120 Design • Dose escalation study • ARM A: RG7597 • ARM A: • ARM B: Cetuximab RG7597+FOLFIRI • ARM B: Cetuximab+FOLFIRI

Primary •Safety/PK •PFS •PFS endpoint

Status • FPI Q4 2010 • FPI July 2012 • Expect FPI Q3 2012

SCCHN=Squamous Cell Carcinoma of the Head and Neck 116 Oncology development programmes

Tumor Immunotherapy

Anti-PD-L1 MAb Molecule (RG7446) Patient Solid tumors Solid tumors population

Phase Phase I Phase I

# of patients N=91 N=68

Design • Dose escalation study • ARM A: RG7446+Avastin • ARM B: RG7446+Avastin+chemotherapy

Primary • Safety/PK • Safety/PK endpoint

Status • FPI Q2 2011 • FPI Q2 2012

117 Oncology development programmes

Antibody drug conjugates (ADCs)

Anti-STEAP1 ADC NME ADC Anti-CD22 ADC NME ADC Molecule (RG7450) (RG7458 ) (RG7593) (RG7596)

Patient Hematologic Hematologic Prostate cancer Ovarian cancer population malignancies malignancies

Phase Phase I Phase I Phase I Phase I # of patients N=49 N=57 N=76 N=99 Design • Dose escalation • Dose escalation • Dose escalation • Dose escalation study study study study

Primary • Safety • Safety/PK • Safety • Safety endpoint

Status • FPI Q1 2011 • FPI Q2 2011 • FPI Q4 2010 • FPI Q1 2011

Collaborator Seattle Genetics Seattle Genetics and Agensys

118 Oncology development programmes

Antibody drug conjugates (ADCs)

NME ADC NME ADC NME ADC NME ADC Molecule (RG7598) (RG7599) (RG7600) (RG7636)

Metastatic or Patient NSCLC and ovarian Pancreatic and Multiple myeloma unresectable population cancer ovarian cancer melanoma

Phase Phase I Phase I Phase I Phase I # of patients N=30-45 N=70 N=66-96 N=44-64 Design • Dose escalation • Dose escalation • Dose escalation • Dose escalation study study study study

Primary • Safety • Safety • Safety • Safety endpoint

Status • FPI Q3 2011 • FPI Q2 2011 • FPI Q4 2011 • FPI Q1 2012

Collaborator Seattle Genetics

119 Oncology development programmes Small molecules

• Phase II studies

PI3K signaling PI3 Kinase inhibitor Molecule (GDC-0941, RG7321) Patient Previously untreated advanced or 2L ER+ metastatic breast cancer population recurrent NSCLC Phase II Phase II Phase FERGI FIGARO # of N=340 N=302 patients Design • ARM A: GDC-0941 plus hormonal therapy • ARM A: GDC-0941 + carboplatin + • ARM B: GDC-0980 plus hormonal therapy paclitaxel • ARM C: Hormonal therapy + placebo • ARM B: Placebo + carboplatin + paclitaxel • ARM C: GDC-0941 + carboplatin + paclitaxel + bevacizumab • ARM D: GDC-0941 + carboplatin + paclitaxel + bevacizumab Primary •PFS •PFS endpoint

Status • FPI Q3 2011 • FPI Q1 2012

120 Oncology development programmes Small molecules (continued)

PI3K signaling PI3 Kinase inhibitor Molecule (GDC-0941, RG7321)

Advanced solid 1L HER2-negative 2L HER2-positive 1L and 2L advanced 2L metastatic non- Patient Advanced solid tumors or Non- metastatic breast metastatic breast non-small cell lung small cell lung population tumors Hodgkin’s cancer cancer cancer cancer Lymphoma

Phase Ia Phase Ia Phase Being conducted Being conducted Phase Ib Phase Ib Phase Ib Phase Ib in the US in the UK

# of patients N=100 N=55 N=45 N=70 N=30 N=30

Design • Dose-escalating • Dose-escalating • Single ARM: • Patients who have • ARM A: GDC-0941 • Single ARM: study study Evaluating GDC- progressed on plus carboplatin/ Evaluating GDC- 0941 plus paclitaxel Herceptin-based paclitaxel (Avastin- 0941 plus Tarceva and Avastin treatment ineligible patients) • ARM A: GDC-0941 • ARM B: GDC-0941 plus T-DM1 plus carboplatin/ • Study includes • ARM B: GDC-0941 paclitaxel plus multiple myeloma plus Herceptin Avastin (Avastin- extension cohort eligible patients)

Primary • Safety • Safety • Safety • Safety • Safety • Safety endpoint

Status • FPI Q4 2007 • FPI Q1 2008 • FPI Q3 2009 • FPI Q3 2009 • FPI Q4 2009 • FPI Q3 2009 • Additional data • Additional data • Data presented at • Data presented at • Data presented at presented at ASCO presented at ASCO SABCS 2011 SABCS 2010 ASCO 2011 2010 and ESMO 2010, ESMO 2010, 2010 and ASCO 2011

121 Oncology development programmes Small molecules (continued)

• Phase II studies

PI3K signaling PI3 Kinase/mTOR dual inhibitor Molecule (GDC-0980, RG7422) Patient 2L ER+ metastatic breast Persistent or recurrent 2L Castration-resistant Renal cell carcinoma population cancer endometrial carcinoma prostate cancer Phase II Phase II Phase Phase II Phase Ib/II ROVER FERGI

# of patients N=80 N=340 N=50 N=262

Design • ARM A: GDC-0980 • ARM A: GDC-0941 plus • Single-arm GDC-0980 • ARM A: GDC-0068 + • ARM B: Everolimus hormonal therapy abiraterone • ARM B: GDC-0980 plus • ARM B: GDC-0980 + hormonal therapy abiraterone • ARM C: Hormonal • ARM C: Placebo + therapy + placebo abiraterone Primary •PFS •PFS •PFS •Safety (PhIB) endpoint • PFS (Ph II)

Status • FPI Q4 2011 • FPI Q3 2011 • FPI Q4 2011 • FPI Q1 2012

122 Oncology development programmes Small molecules (continued)

• Phase I studies

PI3K signaling PI3 Kinase/mTOR dual inhibitor Molecule (GDC-0980, RG7422) Patient Refractory solid tumors Refractory solid tumors Metastatic breast Solid tumors Solid tumors population or NHL or NHL cancer Phase Phase Ia Phase Ia Phase Ib Phase Ib Phase Ib # of patients N=75 N=65 N=65 N=80 N=95 Design • Dose escalation study • Dose escalation study Dose escalation study Dose escalation study • ARM A: GDC-0980 + • ARM A: GDC-0980 • ARM A: GDC-0980 Xeloda plus paclitaxel plus carboplatin and • ARM B: GDC-0980 • ARM B: GDC-0980 paclitaxel plus FOLFOX and plus Avastin and • ARM B: GDC-0980 Avastin paclitaxel plus Avastin, • ARM C: GDC-0980 carboplatin and plus Herceptin and paclitaxel paclitaxel Primary •Safety •Safety •Safety •Safety •Safety endpoint Status • FPI Q2 2009 • FPI Q2 2009 • FPI Q4 2010 • FPI Q2 2011 • FPI Q3 2011 • Data presented at • Data presented at ASCO 2010, ESMO ASCO 2010 and ESMO 2010, and ASCO 2011 2010

ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology. 123 Oncology development programmes Small molecules (continued)

MAPK signaling

MEK inhibitor MEK inhibitor Molecule (GDC-0623, RG7420) (GDC-0973, RG7421)

Metastatic Patient melanoma Solid tumors Solid tumors Solid tumors Solid tumors population BRAF mutation positive Phase Ib Phase Phase I Phase I Phase Ib Phase Ib BRIM7 # of patients N=62 N=90 N=212 N=~50 N=108 Design • Dose escalation • Dose escalation • Dose escalation • Dose escalation • Dose escalation study study study evaluating study evaluating study of GDC-0973 GDC-0973 plus Zelboraf plus GDC- in combination with GDC-0941 (PI3 0973 GDC-0068 Kinase Inhibitor) Primary • Safety/PK • Safety/PK • Safety/PK • Safety/PK • Safety/PK endpoint Status • FPI Q2 2010 • FPI Q2 2007 • FPI Q4 2009 • FPI Q1 2011 • FPI Q2 2012 • Data presented at • Updated data AACR 2011 presented at AACR •Recruitment and ASCO 2012 completed Q3 2011 Collaborator Exelixis 124 Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group Oncology development programmes Small molecules (continued)

AKT inhibitor Molecule (GDC-0068, RG7440)

2L Castration- Patient Solid tumors Solid tumors resistant prostate Solid tumors population cancer

Phase Phase Ia Phase Ib Phase Ib/II Phase I

# of patients N=57 N=90 N=262 N=62 Design • Dose escalation • Dose escalation • ARM A: GDC-0068 • Dose escalations study with either + abiraterone study of GDC-0973* docetaxel or • ARM B: GDC-0980 in combination with fluoropyrimidine + abiraterone GDC-0068 plus oxaliplatin • ARM C: Placebo + abiraterone Primary •Safety/PK • Safety • Safety (Ph IB) •Safety/PK endpoint • PFS (Ph II) Status • FPI Q1 2010 • FPI Q3 2011 • FPI Q1 2012 • FPI Q2 2012 • Data presented at ASCO 2011

Collaborator Array BioPharma

*GDC-0973 in collaboration with Exelixis 125 Oncology development programmes Small molecules (continued)

Bcl-2 selective PI3 Kinase inhibitor PI3 Kinase inhibitor ChK1 inhibitor ChK1 inhibitor Molecule inhibitor (GDC-0032, RG7604) (GDC-0084, RG7666) (GDC-0425, RG7602) (GDC-0575, RG7741) (GDC-0199, RG7601)

Progressive or Relapsed or Patient Solid tumors or Solid tumors or Solid tumors recurrent high- refractory CLL and population lymphoma lymphoma grade glioma NHL

Phase Phase I Phase I Phase IPhase IPhase I

# of patients N=45 N=68 N=75 N=45 N=52 Design • Dose escalation • Dose escalation • Dose escalation • Dose escalation • Dose-escalation study study study study study

Primary • Safety/PK • Safety/PK • Safety/PK • Safety/PK • Safety/PK/Response endpoint rate Status • FPI Q1 2011 • FPI Q2 2012 • FPI Q3 2011 • FPI Q2 2012 • FPI Q2 2011

Collaborator Array BioPharma Abbott and WEHI

WEHI = The Walter and Eliza Hall Institute 126 Immunology development programmes

Anti-LT α Anti-M1 prime Molecule (RG7416) (RG7449)

Patient Rheumatoid Allergic asthma patients- Asthma population arthritis inadequately controlled

Phase IIa Phase IIa Phase IIb Phase/study ALTARA SOLARIO COSTA

# of patients N=210 N=28 N=560

Design • ARM A: Anti-LT alpha plus • ARM A: Anti-M1 prime SC administration on top of SoC DMARD (leflunomide or • ARM B: Placebo •ARM A: RG7449 150mg methotrexate) •ARM B: RG7449 300mg • ARM B: Adalimumab plus •ARM C: RG7449 450mg DMARD (leflunomide or •ARM D: Placebo methotrexate) • ARM C: Placebo plus DMARD (leflunomide or methotrexate)

• Disease Activity Score (DAS28) • Late airway response (LAR) at • Rate of protocol-defined Primary at Day 85 Day 86 exacerbations from baseline to endpoint week 36 Status • FPI Q4 2010 • FPI Q4 2010 • FPI Q2 2012 • Recruitment completed Q2 • Enrollment completed Q2 2011 2012 • Data presented at ATS 2012

DMARD = Disease-Modifying Anti-Rheumatic Drugs 127 Immunology development programmes

Etrolizumab Molecule (rhuMAb-β7, (RG7413) Patient Ulcerative population colitis Phase II Phase/study Phase I EUCALYPTUS

# of patients N=48 N=120

Design • Dose escalation study • ARM A: RhuMAb-β7 (100 mg) plus immunosuppressant • ARM B: RhuMAb-β7 (300 mg) plus immunosuppressant • ARM C: Placebo plus immunosuppressant

Primary • Safety and tolerability • Clinical Remission (Mayo Clinic Score) endpoint at Week 10

Status • Enrolment completed Q3 2010 • FPI Q3 2011

128 Immunology development programmes

Rontalizumab anti-IL17 Molecule (Anti-IFN α, RG7415) (RG7624) Patient Systemic lupus Autoimmune diseases population erythematosus Phase II Phase/study Phase Ib ROSE

# of patients N=238 N=21

Design • ARM A: Placebo • Randomized, double-blind, placebo- • Part 1 – IV controlled, multiple ascending dose • Part 2 - Subcutaneous escalation study • ARM B: Rontalizumab • Part 1 – IV • Part 2 – Subcutaneous

Primary • Proportion of responders at Week 24 • Safety and tolerability endpoint Status • Enrolment completed Q3 2010 • FPI Q1 2012 • Data to be presented in H2 2012 • Enrollment completed Q2 2012

Collaborator NovImmune

129 Neuroscience and ophthalmology development programmes

Crenezumab Anti-Factor D Molecule (Anti-Αβ, RG7412) (RG7417) Geographic atrophy (GA) Patient Alzheimer’s secondary to age-related macular population Disease degeneration Phase II Phase II Phase Ib/II Phase/study ABBY BLAZE MAHALO Cognition study Biomarker study

# of patients N=360 N=72 N=143

Design • ARM A: Anti-Abeta • ARM A: Anti-Abeta • Part 1: Open-label subcutaneous subcutaneous • Multiple dosing • ARM B: Anti-Abeta IV • ARM B: Anti-Abeta IV • Part 2: Randomised • ARM C: Placebo • ARM C: Placebo • ARM A: Anti-Factor D injection • ARM B: Sham Injection

Primary • Change in cognition • Change in brain amyloid load • Part 1: Safety endpoint (ADAS-cog) and Clinical from baseline to week 69 • Part 2: Growth rate of GA lesions at Dementia Rating, Sum of months 12 Boxes (CDR-SOB) score from baseline to week 73 Status • FPI Q2 2011 • FPI Q3 2011 • Part 1 FPI Q4 2012 • Enrollment completed July • Part 2 FPI Q2 2011 2012 • Enrollment completed Q4 2011

Collaborator AC Immune

130 Metabolism and virology development programmes

Anti-oxLDL Anti-PCSK9 NME Molecule (RG7418, BI-204) (RG7652) (RG7667)

Secondary prevention of Patient cardiovascular events in Metabolic diseases Infectious diseases population patients with ACS

Phase II Phase II Phase/study Phase I Proof of activity study EQUATOR

# of patients N=144 N=224 N=181

Design • ARM A: Anti-oxLDL (single SC dosing every 4 weeks • RG7667 dose) and statin •Experimental: five different • Placebo • ARM B: Anti-oxLDL doses of RG7652 (repeating dose) and statin •Placebo • ARM C: Placebo and statin

Primary • Change in TBR as measured • Absolute change from •Safety, PK endpoint by FDG-PET/CT at week 12 baseline in LDL-c concentration

Status • FPI Q1 2011 • FPI Q2 2012 • FPI Q1 2012 • Recruitment completed Q1 2012

Collaborator BioInvent

ACS – acute coronary syndrome; TBR = Target-to-background ratio; FDG = Fluoro-2-deoxy-D-glucose; PET = Positron Emission Tomography; CT = CAT scan. 131 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group HY 2012 results

Diagnostics

Foreign exchange rate information 132 Geographical sales split by divisions and Group*

CHF m HY 2011 HY 2012 % change CER Pharmaceutical Division 16,815 17,409 +4 United States 6,285 6,815 +6 Western Europe 4,299 4,000 -3 Japan 1,831 1,943 +1 International 4,400 4,651 +8 Diagnostics Division 4,856 5,014 +5 United States 1,051 1,145 +6 Western Europe 1,926 1,821 -1 Japan 253 284 +7 International 1,626 1,764 +11 Group 21,671 22,423 +4 United States 7,336 7,960 +6 Western Europe 6,225 5,821 -2 Japan 2,084 2,227 +1 International 6,026 6,415 +9 133 * Geographical sales split shown here does not represent operational organization; CER = Constant Exchange Rates Pharma Division sales HY 2012 (vs. 2011) Top 20 products Global US WE Japan International CHF m % CER CHF m % CER CHF m % CER CHF m % CER CHF m % CER MabThera/Rituxan 3,315 9 1,557 8 823 6 136 12 799 13 Herceptin 2,951 11 816 10 992 3 157 -3 986 22 Avastin 2,805 3 1,239 -2 734 2 345 12 487 15 Pegasys 903 31 307 122 165 4 39 -24 392 15 Xeloda 763 14 316 27 129 -3 60 6 258 12 Lucentis 745 -5 745 -5 ------Tarceva 666 8 278 19 169 -8 53 19 166 10 CellCept 454 -15 78 -28 121 -20 36 16 219 -10 Actemra/RoActemra 385 39 107 72 124 38 93 4 61 67 NeoRec./Epogin 351 -28 - - 135 -15 90 -53 126 -10 Xolair 345 12 345 12 ------Valcyte/Cymevene 307 9 154 19 79 0 - - 74 4 Activase/TNKase 285 21 262 21 - - - - 23 16 Pulmozyme 257 4 158 9 50 0 - - 49 -4 Tamiflu 221 -18 90 -50 7 -21 95 77 29 16 Bonviva/Boniva 207 -46 63 -65 64 -46 - - 80 -10 Mircera 177 30 - - 41 -53 88 - 48 4 Madopar 157 8 - - 45 0 10 -12 102 14 Nutropin 154 -11 151 -10 - - - - 3 -14 Rocephin 133 2 1 1 25 -14 25 -10 82 13 134 CER=Constant Exchange Rates Pharma Division sales HY 2012 (vs. 2011) Recently launched products

Global US WE Japan International CHF m % CER CHF m % CER CHF m % CER CHF m % CER CHF m % CER

Actemra/RoActemra 385 39 107 72 124 38 93 4 61 67 Mircera 177 30 - - 41 -53 88 - 48 4 Zelboraf 92 - 57 - 35 - - - - - Erivedge 10 - 10 ------Perjeta 4-4------

135 CER=Constant Exchange Rates Pharma Division CER sales growth1 in % Global top 20 products

Q2/11 Q3/11 Q4/11 Q1/12 Q2/12 MabThera/Rituxan 6 7 10 7 11 Herceptin 12 4 14 7 14 Avastin -9 -10 -2 1 5 Pegasys -7 6 5 32 29 Xeloda210131513 Lucentis 29 17 13 0 -11 Tarceva11010107 CellCept -13 -9 -20 -19 -11 Actemra/RoActemra 90 69 48 46 32 NeoRec./Epogin -18 -28 -27 -28 -28 Xolair 9 9 12 12 12 Valcyte/Cymevene 10 8 2 9 10 Activase/TNKase 18 5 15 17 25 Pulmozyme 9 11 12 1 8 Tamiflu -88 -51 -19 -24 63 Bonviva/Boniva -19 -24 -30 -31 -64 Mircera 21 82 63 34 25 Madopar 7 8 1 4 11 Nutropin 1 -21 -15 -9 -12 Rocephin -19 -6 7 3 0 136 1 Q2-Q4/11 vs. Q2-Q4/10, Q1-Q2/12 vs. Q1-Q2/11 CER=Constant Exchange Rates Pharma Division CER sales growth1 in % Top 20 products by region US Western Europe Japan International Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 MabThera/Rituxan 7 5 8 9 8 10 6 6 -1 -3 8 16 9 25 5 21 Herceptin 4 7 11 9 4 9 2 4 -23 4 10 -12 9 32 10 36 Avastin -16 -9 0 -5 -9 -3 -2 6 2 2 8 16 5 17 4 26 Pegasys 15 47 144 104 -10 -8 1 8 -28 -35 -29 -20 15 -1 14 16 Xeloda 23 22 31 24 -1 -8 -1 -4 -9 -9 1 10 6 24 11 13 Lucentis 17 13 0 -11 ------Tarceva 7 16 18 21 6 -9 -7 -8 2 2 9 28 23 33 20 -1 CellCept 2 -14 -38 -19 -35 -34 -23 -17 15 7 16 16 5 -14 -13 -7 Actemra/RoActemra153 92 87 61 51 52 41 35 25 15 8 1 177 79 91 49 NeoRec./Epogin - - - - -26 -23 -20 -10 -42 -42 -48 -58 -8 -7 -15 -5 Xolair 9 12 12 12 ------Valcyte/Cymevene -4 0 12 26 8 6 1 -1 - - - - 42 3 12 -4 Activase/TNKase 5 17 19 24 ------7 -4 2 30 Pulmozyme 14 5 8 11 5 1 1 -2 - - - - 12 43 -16 10 Tamiflu - - -56 51 * - -36 44 -55 3 85 -14 -62 205 -16 193 Bonviva/Boniva -36 -36 -32 - -21 -34 -45 -46 - - - - 7 -8 -10 -11 Mircera - - - - 15 2 -25 -79 - - - - 65 35 1 6 Madopar - - - - 6 -4 0 0 -2 -16 -16 -7 10 7 9 20 Nutropin -21 -15 -9 -12 ------1 -17 -4 -24 Rocephin - - 1 2 -16 17 -12 -17 -4 -2 -8 -12 -5 5 14 12 137 1 Q3-Q4 2011 vs. 2010, Q1-Q2 2012 vs. 2011 CER=Constant Exchange Rates * > 500% CER sales growth (%) Quarterly development

2011 vs. 2010 2012 vs. 2011 Q1 Q2 Q3 Q4 Q1 Q2

Pharmaceuticals Division -2 -1 0 3 2 6

United States 2 1 1 4 6 6 Western Europe -4 -4 -3 -1 -4 -1 Japan -7 -3 -7 -5 1 0 International -3 0 5 10 2 14 Diagnostics Division 6 5 6 7 4 6 Roche Group 0 0 1 4 2 6

138 CER=Constant Exchange Rates HY 2012: Oncology franchise

Oncology sales US 1 12 +8% • Sales growth driven by Rituxan, Herceptin, Xeloda and Zelboraf 10 +4% Western Europe 8 +15% • Continued growth of MabThera, Zelboraf and Herceptin; Avastin back to growth 6

CHF bn +3% International 4 • Double-digit growth for major oncology products 2 +8% Japan 0 HY '07 HY '08 HY '09 HY '10 HY '11 HY '12 • Growth driven by Avastin, MabThera and Tarceva Japan International Western Europe US

139 1 CER=Constant Exchange Rates; HY 2012 Oncology sales CHF 10.5 bn MabThera/Rituxan

Global sales Regional sales CER growth +9%1 3.6 US +8% 3

2.4 International +13% 1.8 CHF bn 1.2 Japan +12% 0.6 Western Europe +6%

0 HY '07 HY '08 HY '09 HY '10 HY '11 HY '12

HY 2012 sales of CHF 3.315 bn

• 1L FL maintenance indication remains the major 2012 growth driver for MabThera in WE and US)

• Growth in emerging markets driven by uptake in NHL indications; China continued patient share growth and longer treatment duration in DLBCL

140 1 CER=Constant Exchange Rates Herceptin

Global sales Regional sales CER growth +11%1 3.5 Western Europe +3% 3.0 2.5 US +10% 2.0

CHF bn 1.5 1.0 Japan -3% 0.5 International +22% 0.0 HY '07 HY '08 HY '09 HY '10 HY '11 HY '12 HY 2012 sales of CHF 2.951 bn • US: Demand growth driven by mGC uptake, increased BC testing • China: mainly driven by increase in new patients through continued PAP activities driving access and HER2 testing initiatives (penetration, quality) • Expanded access in international markets ongoing

141 1 CER; 2 penetration is reported as Herceptin eligible patients in the US, and as total patient share in top 5 EU Avastin

Global sales Regional sales CER growth

3.5 US -2% +3%1 3.0 2.5 Japan +12% 2.0 CHF bn 1.5 International +15% 1.0 0.5 Western Europe +2% 0.0 HY '07 HY '08 HY '09 HY '10 HY '11 HY '12 HY 2012 sales of CHF 2.950 bn • WE : successful launch in Ovarian cancer; increased use in mBC, mainly driven by 3N mBC. • US: lower wholesaler inventories at the end of June 2012 and lower use in breast cancer compared to the first half of 2011 • Japan: driven by further uptake in NSCLC and mBC

142 1 CER=Constant Exchange Rates Xeloda

Global sales Regional sales CER growth 1 +14% International +12% 800 700 600 Western Europe -3% 500 400 CHF m Japan +6% 300 200 100 US +27% 0 HY '07 HY '08 HY '09 HY '10 HY '11 HY '12

HY 2012 sales of CHF 763 m • US: increased demand partly due to shortage of 5FU. • Sales growth in the International region driven by China and Latin America • WE sales impacted by pricing pressure

143 CER=Constant Exchange Rates Tarceva

Global sales Regional sales CER growth 1 +8% Western Europe -8% 700 600 Japan +19% 500 400 300

CHF m US +19% 200 100 0 International +10% HY '07 HY '08 HY '09 HY '10 HY '11 HY '12

HY 2012 sales of CHF 666 m • US: driven by increased EGFR testing rates, 1L treatment rates for Mut+ve patients and increase in 1L maintenance use for squamous patients • EU: Pricing pressure and competitive challenges • Japan: sales growth driven by uptake in 2L NSCLC

144 CER=Constant Exchange Rates Inflammation/Autoimmune/Transplantation

IAT sales HY 2012 IAT sales: CHF 1.48 bn • Strong growth of Actemra and 1.8 MabThera/Rituxan compensated for the +4%1 further CellCept decline in US and WE 1.5 -2% 1.2 Actemra/RoActemra +3% Sales: CHF 385 m (+39%) 0.9 • Further gain of patient share in all treatment

CHF bn 0.6 0% lines according to label; US biggest growth contributor 0.3 +12% CellCept 0.0 HY '07 HY '08 HY '09 HY '10 HY '11 HY '12 Sales: CHF 454 m (-15%) • Patent expiry key EU countries end 2010 Japan International Western Europe US

145 1 CER=Constant Exchange Rates Tamiflu quarterly sales 2008 - 2012 Retail and Governments/Corporations

CHF m 1150 Retail Governments & Corporations 950 267 663 750

550 260 95

350 97 727 533 422 349 23 233 150 75 304 7 177 65 170 48 26 106 91 7 12 50 36 19 45 46 -1 17 3 -50 -6 10 8 Q2 08 Q3 08 Q4 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12

146 HY 2012: Group sales +4% CER sales growth

+6% -3% +1%+8% +5% +4% +3%

-112 Pharma Division +242 +4%

+355 +863 +751

-107 +14

+359

Q1/12 +184 -78 +13 +53 +92 +264 -357 -93 United Western Japan Intl Dia Group Fx1 Group States Europe Divsion CHF

147 1 avg December 2011 to avg HY 2012 fx Absolute values at Constant Exchange Rates (CER, at avg full year 2011) HY 2012: Group net debt development

CHF bn Free Cash Flow CHF -1.3 bn 0 35 % higher outflow than in HY 2011

Pharma Division-,8.4 6.6 Taxes -,8.4 -1.5 Dia Division 0.8 Treasury -1.1 Corporate -0.3 Dividends -5.9 -15.6 -,16.9 -17.3

+7.2 -8.5 +7 % CER -0.5

Net debt Operating Free Non-operating Currency Net debt 31 Dec 11 Cash Flow free cash flow translation, 30 Jun 12 fair value & other movements 148 CER=Constant Exchange Rates Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group HY 2012 results

Diagnostics

Foreign exchange rate information 149 HY 2012: Diagnostics Division CER growth By Region and Business Area (vs. 2011)

Global North America EMEA RoW % CER % CER % CER % CER CHFm growth CHFm growth CHFm growth CHFm growth

Professional Diagnostics 2,515 9 475 9 1,203 4 837 16 Diabetes Care 1,260 -2 275 -1 730 -5 255 11 Molecular Diagnostics 571 6 198 6 223 6 150 6 Applied Science 363 -3 138 -6 135 -5 90 5 Tissue Diagnostics 305 17 195 12 74 23 36 33 Diagnostics Division 5,014 5 1,281 5 2,365 1 1,368 14

150 CER=Constant Exchange Rates Diagnostics Division quarterly sales and CER growth1

Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Professional 1,171 10 1,189 7 1,087 10 1,262 8 1,224 9 1,291 8 Diagnostics Diabetes 637 1 679 2 605 2 731 5 564 -7 696 3 Care Molecular 274 3 270 2 257 3 293 9 285 8 286 4 Diagnostics Applied 198 -3 179 -5 167 1 196 -6 183 -4 180 -2 Science Tissue 128 18 131 15 123 11 160 17 147 18 158 16 Diagnostics

Dia Division 2,408 6 2,448 5 2,239 6 2,642 7 2,403 4 2,611 6

1 versus same period of prior year CER = Constant Exchange Rates 151 2011 sales restated from Diabetes Care (full year impact CHF –23 m) to Professional Diagnostics (CHF +23 m full year impact) Diagnostics Division sales HY 2012 Growth driven by Professional and Tissue Diagnostics

CHF 5,014 m CER sales growth

1,260 Diabetes Care 25% Diagnostics Division 5% Diabetes -2% Applied Science 7% Care 363 Professional Diagnostics 9% Molecular 6% 571 Molecular Diagnostics 12% Diagnostics 2,515 Applied Science -3% 305 Tissue Diagnostics 6% Tissue Diagnostics 17% Professional Diagnostics 50%

152 CER=Constant Exchange Rates Diagnostics Division sales HY 2012 Growth driven by Asia Pacific and North America

CHF 5,014 m CER sales growth

1,281 North America 25% Diagnostics Division 5%

North 5% America 348 Latin America 7% EMEA* 1% Asia Pacific 15% Latin 736 13% 2,365 America Asia 284 Japan 6% Pacific 17% EMEA1 47% Japan 7%

153 1 Europe, Middle East and Africa CER=Constant Exchange Rates Professional Diagnostics Strong growth driven by immunoassays

2012 vs. 2011 CHF bn CER growth 2.7 +9%

+4% 1.8 +6%

0.9 +14%

0.0 HY '10 HY'11 HY'12

Other POC products Clinical Chemistry Immunoassay

154 CER=Constant Exchange Rates Diabetes Care Reimbursement pressures in EMEA

1.5 CHF bn 2012 vs. 2011 CER growth -2% 1.0 +12%

0.5 -3%

0.0 HY '10 HY'11 HY'12 Blood Glucose Insulin Delivery

155 CER=Constant Exchange Rates Molecular Diagnostics Strong performance in blood screening

CHF m 2012 vs. 2011 CER growth 700 +6% 600

500

400 +12% 300

200 +3% 100

0 HY '10 HY'11 HY'12

Other Blood Screening Virology

156 CER=Constant Exchange Rates Applied Science Restructuring to focus on key areas

500 CHF m

2012 vs. 2011 400 CER growth -3% 300

200 -18% +9% 100 +2% 0 HY'10 HY'11 HY'12 qPCR&NAP Custom Biotech

Genomics Other 157 CER=Constant Exchange Rates Tissue Diagnostics Continued strong growth ahead of the market

2012 vs. 2011 CHF m CER growth

320 +17%

+9% 240

160 +18%

80

0 HY '10 HY '11 HY '12

Other Primary Staining Advanced Staining

158 CER=Constant Exchange Rates 2012: Key planned product launches Professional Diagnostics

Product Description Region

cobas t 611 Coagulation analyser for mid and high-throughput EU screening in labs cobas b 123 POC Benchtop multi-parameter blood gas analyzer for use in US  critical care settings at the point of care

cobas b 101 Multi-parameter blood lipid and glucose analyser at the EU point of care Elecsys Vitamin D Measures vitamin D2 and D3 with greater precision US assay Elecsys HE4 Detects tumour marker HE4 for risk assessment of early US immunoassay ovarian cancer in patients with pelvic mass (with biomarker CA125)

159 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors EU = European Union; US = United States 2012: Key planned product launches Diabetes Care

Product Description Region

Accu-Chek Mobile Next-generation strip-free blood glucose monitoring EU  system with an integrated lancing device

Accu-Chek Nano Small and sleek blood glucose monitoring meter with US  SmartView enhanced functions, requiring no coding of test strips

Accu-Chek Combo Interactive insulin delivery system combining an insulin US  pump (Accu-Chek Spirit Combo) and a blood glucose meter (Accu-Chek Aviva Combo) with broad data management capabilities SOLO Micropump Insulin micro pump and blood glucose meter that functions EU as a handheld controller

160 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors EU=European Union; US=United States 2012: Key planned product launches Molecular Diagnostics

Product Description Region

cobas 4800 CT/NG Detection of chlamydia and gonorrhoea infections US  Test CAP/CTM CMV Detection and monitoring of cytomegalovirus infections US  Test

161 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors EU=European Union; US=United States 2012: Key planned product launches Applied Science

Product Description Region

GS GType Gene sequencing primer sets for leukemia research WW  TET2/CBL/KRAS & RUNX1 Primer Sets

162 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors EU=European Union; US=United States ; WW=Worldwide 2012: Key planned product launches Tissue Diagnostics

Product Description Region

BenchMark Special Fully automated tissue stainer WW  Stains VENTANA iScan HT High-throughput scanner that enables digital viewing of WW  tissue slides CINtec p16 Histology IHC (immunohistochemistry) assay for early detection of EU, US cervical cancer ER test Estrogen receptor antibody (IHC) assay to support the US diagnosis of breast cancer

163 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors EU=European Union; US=United States; WW=Worldwide Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group HY 2012 results

Diagnostics

Foreign exchange rate information 164 Exchange rate impact on sales growth For HY, negative impact from EUR almost compensated by positive impact from USD and JPY Development of average exchange rates versus prior year period CHF / EUR -6.1 % -5.2 % CHF / USD -2.2 % +2.5 % CHF / JPY +1.5 % +5.3 %

Difference in CHF / CER -3.3 %pt -0.6 %pt growth 4.1% 3.5% 2.5% Sales growth CER CHF 2012 growth growth vs. 2011 -0.8%

Q1 HY YTD 9 FY 165 CER=Constant Exchange Rates (avg full year 2011) Exchange rate impact on sales growth Q2 negative EUR impact more than offset by positive USD impact Development of average exchange rates versus prior year period CHF / EUR -6.1 % -4.2 % CHF / USD -2.2 % +7.4 % CHF / JPY +1.5 % +9.5 % Difference in CHF / CER -3.3 %pt +2.3 %pt growth 8.0%

5.7%

Sales 2.5% growth CER CHF 2012 growth growth vs. 2011 -0.8% Q1 Q2 Q3 Q4 166 CER=Constant Exchange Rates (avg full year 2011) Exchange rate impact on sales growth Negative impact in particular from EUR almost offset by positive impact mainly from USD and JPY

-1.3% +0.3%

CER +0.5% sales -0.5% CHF growth 4.1% +0.9% H1 2012 -0.4% sales -0.1% growth vs. 3.5% H1 2011 H1 2012 vs. H1 2011

CER EUR Oth Lat-Am Other USD JPY As-Pac CHF Europe 167 CER=Constant Exchange Rates (avg full year 2011) CHF / USD

1.00 Monthly averages 0.95 2012 0.90 0.85 2011 0.80 0.75

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

1.00 Year-To-Date averages 0.95 2012 0.90 0.85 -2% +2% 2011 0.80 0.75

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 168 CHF / USD

1.00

monthly avg 2012 0.95 average YTD 06 2012 +2% 0.90 average YTD 06 2011 average full year 2011

0.85

0.80 monthly avg 2011

0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 169 CHF / EUR

Monthly averages 1.35 1.30 2011 1.25 1.20 1.15 2012 1.10

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

1.35 Year-To-Date averages 1.30 2011 1.25 -6% -5% 1.20 2012 1.15 1.10

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 170 CHF / EUR

1.35

1.30 average YTD 06 2011

average full year 2011 1.25 -5% average YTD 06 2012 1.20 monthly avg 2012

1.15 monthly avg 2011

1.10 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 171 We Innovate Healthcare

172